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Abstract

Magnetic resonance (MR) has outstanding potential as a noninvasive imaging modality.
Possessing spatial resolution at the millimeter scale, MR imaging of anatomical features
is unrivalled by other imaging techniques. Although MR imaging has outstanding spatial
resolution it suffers from inherently low signal intensity. With a low sensitivity, the
signal to noise ratio is low; thus MRI scans may take upwards of an hour to generate an
acceptable image without a contrast agent. This drawback clearly justifies the need for
contrast agents and the long held interest in their development.

Our development of novel MRI contrast agents focuses on the synthesis and evaluation of
cyclen based agents for magnetic resonance spectroscopy (MRS), spin-lattice relaxation
(T1), spin-spin relaxation (T2) and paramagnetic chemical exchange saturation transfer
(ParaCEST).

Chapters 2 and 3 discuss contrast agents based on tetra(propargyl) DOTAM lanthanide
complexes for magnetic resonance spectroscopy (MRS), relaxation and ParaCEST. With
respect to MRS, temperature sensitivity values from 1.05 ppm/°C to 1.76 ppm/°C were
determined, which represents a 2–3 fold improvement over currently available lanthanide
temperature-responsive

contrast

agents.

Tetra(propargyl)

DOTAM

was

further

functionalized through Huisgen “click” chemistry reactions with a glucosyl azide. These
complexes were characterized by a combination of 1HNMR, single-crystal X-ray
crystallography, relaxation and CEST experiments.

Chapter 4 focuses on the evaluation of a highly shifted amide suitable for ParaCEST
imaging. The Tm3+ chelate of DOTAM [1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10tetraazacyclododecane] possessing sterically demanding t-butyl amide substitution favors
TSAP geometry. This geometry shifts the amide signal to -100 ppm, which is beyond the
frequency of macromolecule magnetization transfer and thus represents a prototype
contrast agent for potential in vivo use.
ii

Chapter 5 discusses a series of Dy3+ and Tm3+ tetra(substituted) DOTAM paraCEST
agents incorporating para-substituted anilines. The aniline and p-methoxyaniline agents
response to changes in pH near the physiologic range have been evaluated. Two distinct
amide signals are observed in the CEST spectrum for Tm3+-p-methoxyaniline complex,
corresponding to SAP and TSAP isomers. A crystal structure of this agent indicates
TSAP geometry with the absence of an inner sphere water molecule. Due to the lack of
coordinated water, this agent produces minimal shortening of T2 relaxation time
constants. The benefit of a long T2 relaxation is demonstrated in the higher signal to
noise ratio for the agent that does not contain an inner sphere water compared to agents
that have bound water.
Chapter 6 discusses a water soluble gold nanoparticle (AuNP) conjugated to over 50 Gd3+
chelators which has been prepared using an interfacial Michael addition. The agent was
determined to be non-acutely toxic to mice and T1-weighted in vivo images of mouse
kidneys were obtained.

Keywords
Magnetic resonance imaging, MRI, Lanthanides, Paramagnetic resonance saturation
transfer, ParaCEST, Chemical exchange saturation transfer, CEST, Relaxation, Contrast
agent.
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Introduction
1.1 Magnetic Resonance Imaging (MRI)

Magnetic resonance (MR) has become one of the leading imaging modalities used
clinically for diagnosis of disease and imaging of structural anatomy. Over a 30 year
period between the 1950s and the 1980s, MRI developed from building on previously
known nuclear magnetic resonance (NMR) techniques to evaluate relaxation of 1H and
other nuclei in vivo. The current state of the art technology uses field gradients to create
millimeter thick slices, which allow for the detailed acquisition of 2D and 3D images.
With the fundamental technology based on NMR, MRI uses a radio frequency as the
source of excitation during imaging, which has been shown to have no detrimental effects
on patients. As a noninvasive imaging tool MRI has the potential to be less harmful
compared to other imaging modalities that acquire similar images, such as, computer
tomography (CT) which use X-Rays and positron emission tomography (PET) which
uses radioactive materials. With patient safety in mind, MRI as a noninvasive imaging
technique can be applied to a patient numerous times, with negligible side effects. This
cannot be said for other imaging modalities that generate detrimental side effects due to
the use of ionizing radiation as used in CT scans or the use of radioactive material in PET
scans.

To understand how MR images are acquired, one must first have a basic

understanding of the theory of NMR.
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With the goal of developing novel MRI contrast agents (CA) we are concerned with the
observation of in vivo 1H nuclei. Sources of 1H nuclei are plentiful; however, this thesis
will focus on bulk water 1H nuclei, exchangeable and nonexchangeable 1H nuclei of CAs.
Accordingly, a brief explanation of the principals of MRI and NMR with respect to 1H
will be discussed.

In 1946 two research groups (F. Bloch, W.W. Hansen, M.E. Packard and E. M. Purcell,
H. C. Torrey, R. V. Pound) independently discovered the phenomenon of nuclear
magnetic resonance with Bloch and Purcell sharing the Nobel prize in physics (1952) for
their contributions.1 1H NMR spectroscopy is possible because of the interaction of the
nucleus with a magnetic field, causing an angular momentum (P), which can be
calculated by equation 1.1.1

Where h is Plank’s constant and I is the nuclear spin quantum number equal to ± ½ for
hydrogen atoms. Because a hydrogen atom has a nonzero value for the spin quantum
number a 1H nucleus will also have a magnetic momentum (µ) which can be calculated
by equation 1.2.1

Where γ is the gyromagnetic ratio of hydrogen (26.75 107 rad T-1 s-1 or 42.577 MHz T-1).
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If hydrogen atoms are then placed into a magnetic field (B0) the angular momentum splits
into two possible orientations, either aligned with (+ ½ ) or against the magnetic field (½ ). This can be calculated from equation 1.3.1

Where m is the magnetic quantum number, I = ½ for hydrogen atoms.

In NMR

spectroscopy, the z axis is conventionally chosen as the magnetic field direction. When
the 1H nuclei are subjected to a magnetic field they will begin to precess around axis of
the magnetic field. The frequency in which the protons will precess around the axis (ν,
Larmor frequency) is proportional to the field strength of the magnet and can be
calculated in equation 1.4.1

0

As an example for NMR spectroscopy, a 1H nucleus exposed to a field strength of 9.4 T
will have a Larmor frequency of 400 MHz. The distribution of the two energy states (±
½ ) is defined by a Boltzmann distribution, with a larger population being aligned with
the magnetic field, or in a lower energy state. The difference in energy state population is
defined as a vector with the macroscopic magnetization defined as M0 along the z axis.
Irradiation at the Larmor frequency using a Rf pulse (B1) will move M0 away from the z
axis and onto either the x or y axis, where the receiver is situated to measure the energy
released during relaxation (Figure 1.1).
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Figure 1.1. Representation of net magnetization vector (M0) a) At equilibrium before a
B1 is applied (M0 = Mz). b) After a 90° B1 is applied (M0 = Mx). c) After a 180° B1 is
applied (M0 = M-z).

As the 1H nucleus begin to relax, their frequency of precession can be measured as the
excess energy is released. The process of the data acquisition is not needed to understand
the basic NMR theory in this thesis and will not be discussed further.

In NMR

spectroscopy the different chemical environments in which the 1H nuclei are bonded will
lead to different precession frequencies. As relaxation occurs, the various frequencies are
measured and displayed in either Hertz (Hz) or parts per million (ppm) to identify the
environment of the proton and are typically referenced to the frequency of the 1H nuclei
resonance of tetramethylsilane (TMS) for organic molecules. With respect to MRI, we
are focused on a single chemical environment of 1H nuclei (water) and therefore the
majority of the 1H nuclei will precess at the same frequency for a given B0. One of the
main reasons to use MR as an imaging technique is due to its excellent spatial resolution.
The spatial resolution is achieved by acquiring a large number of “slices” or “planes”
with resolution thicknesses as little as 100 µm. To achieve the different planes or slices it
is necessary to create a gradient of magnetic field strength along the specimen being
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imaged.

This creates a number of different micro fields all with different Larmor

frequencies for protons. Using equation 1.4, its can be seen as B0 changes so does the
Larmor frequency and therefore only areas with equivalent B0 can be imaged
simultaneously as slices. Protons that do not have the same B0 will not be affected by the
Rf pulse and therefore will not be observable during the imaging. These micro variations
allow for sub-millimeter precision when acquiring a MR image.

Relaxation occurs after the Rf pulse is turned off. At this point the net magnetization has
been flipped onto the x or y axis now begins to relax back to the resting state. Relaxation
occurs through two mechanisms.

The first is spin-lattice relaxation or longitudinal

relaxation (T1). T1 relaxation is defined as when the magnetization returns to the z axis.
This is enhanced by the interaction of the excited 1H nucleus with its surroundings to
release energy. The surroundings in NMR can be other molecules or the NMR tube.
With respect to MRI the energy can be transferred to the surrounding tissue. The second
is spin-spin relaxation or transverse relaxation (T2). After the Rf pulse has aligned the M0
vector onto the x or y-axis the signals are bunched together in what is called phase
coherence.1 The T2 is a measurement of how quickly the in-phase signals become out of
phase. This happens spontaneously as the protons start to precess and interact with other
protons. T2 relaxation can be enhanced by magnetic field (B0) inhomogeneity. Equation
1.4 shows that protons at a higher field should precess more quickly than those at a lower
field. This difference in precession rate will dephase the signals and lead to a signal
decrease.
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1.2

Contrast Agents

An MRI contrast agent is any medium that aids in the acquisition of an image or
enhances the information gained from an image. While MRI does not necessarily need a
contrast agent, the use of CAs has shown to significantly enhance the images and due to
this, roughly 50% of all MR images use some form of CA.2

The enhancement of the

signal can be accomplished in a number of ways, such as, shortening the scan time
needed to acquire a similar image without agent, enhancement of regions that were not
visible without an agent and measuring physiological conditions (pH, temperature). The
latter does not necessarily enhance the image but rather gains information that would not
be otherwise available. In MRI, the first generation of CAs were designed to increase the
relaxation of the 1H nuclei of water. The agents are typically referred to as T1 or T2
agents and their definition depends on which relaxation pathway is enhanced to a greater
effect. T1 agents are described as agents that increase relaxation through spin-latice and
are usually incorporate a Gd3+ ion, while T2 agents enhance spin-spin relaxation and
typically use iron oxide nanoparticles to generate the contrast. However, new agents
called T2-exchange agents have recently been developed using lanthanides to reduce the
T2. In general, T1 agents will increase the signal where the agent is located, while T2 will
decrease the signal, causing a darkening of the resulting image. The third design of MRI
CAs that will be discussed are ParaCEST agents. These agents rely on saturation transfer
between the CA and the surrounding water to decrease the overall water signal,
generating contrast.

7

1.2.1

T1-Based Contrast Agents

Gadolinium based T1 agents were first developed in the 1980s with the first clinically
accepted Gd3+ CA (Magnevist) approved in 1987.

Magnevist was designed using

diethylenetriaminepentaacetic acid (DTPA) as a chelating moiety around a Gd3+ ion
(Figure 1.2). Using the eight donating sites of DTPA to coordinate the Gd3+ left a single
site on the lanthanide open to allow for exchangeable water, as lanthanides have a nine
site coordination sphere. The exchangeable water molecule (bound water) is used to
transfer the efficient T1 relaxation of the 7 unpaired electrons of Gd3+ to the bulk
solvating water molecules. Paramagnetic molecules, especially Gd3+ with 7 unpaired
electrons, have the ability to reduce the T1 of 1H nuclei substantially. This is due to the
high magnetic moment of unpaired electrons (658 times stronger than a proton).3 Since
the development of Magnevist there has been research into the development of new
agents that are more efficient (lower dose) and form more stable chelates, to limit toxicity
of the lanthanide ions. The stability of lanthanide based contrast agents is essential, as
free lanthanides are toxic. The syndrome nephrogenic systemic fibrosis has been linked
to patients that have been administered gadolinium contrast agents.4, 5 Thus, patients with
impaired kidney functions, who cannot eliminate the CA quickly, will typically not be
imaged using a CA. Due to the possibility of toxic side effects, macrocyclic 1,4,7,10tetraazacyclododecane (cyclen) has been used to develop a number of clinically available
CAs, as the macrocyclic chelator has been shown to be more stable in vivo and for this
reason is our choice of chelator for our development of novel CAs.6, 7 The simplest of the
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macrocyclic CAs is Gd3+ 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(Dotarem, Figure 1.2) which was accepted as a CA in the 1990s.

Figure 1.2. Left) Chemical structure of the first clinically available T1 contrast agent. A
Gd3+ ion is chelated with DTPA. Right) A Gd3+ contrast agent using a macrocyclic
chelator.

In aid of designing more efficient Gd3+ CAs, mathematical models of the processes of
relaxation have been developed, most notably by Bloembergen, Solomon and Morgan,
and can traced to the Bloch equations. 3 The relaxivity (r1) of a Gd3+ CA is described by
the time for T1 relaxation to occur at 1 mM concentration of the CA (eq. 1.5).3

1( bs)

1

1(W)

Where T1(Obs) is the bulk water T1 measured in the presence of a paramagnetic species.
T1(W) is the T1 measured without any paramagnetic species. r1 is the relaxivity of the agent
(mM-1 s-1) and [Gd] is the concentration of gadolinium present (mM). The relaxivity of
an agent can further be evaluated by the inner sphere (is) coordinating water, in equation
1.6, where the exchange rate and number of coordinated water molecules are taken into
account.3

is
1

1m

m
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Where c is the concentration of agent, q is the number of coordinated water molecule(s),

τm is the lifetime of the bound water and 1/T1m is the longitudinal inner-sphere relaxation
rate. From these two equations it is obvious that a higher number of coordinated water
molecules and a lower bound water lifetime will give rise to a more efficient CA. The
limitation on this however is the toxicity of the agent if the metal is not coordinated
strongly, which can occur as the q value is increased.

There are agents under

development that contain more than a single bound water,8 but these will not be discussed
in this thesis. A vast number of equations have been developed and their use in fully
characterizing T1 based CAs is possible. Typically to solve these equations and extract
all the parameters that affect T1 relaxation, one would need to perform NMR field cycling
experiments, electron paramagnetic resonance studies and liquid NMR of various
pressures.6,
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In chapter 3, field cycling spectra were acquired but the relevant Bloch

equations were not solved for the relaxation parameters.

While it is possible to solve

relaxation parameters associated with T1 based CAs, our focus of T1 based contrast
agents was the development of new synthetic methods to conjugate cyclen to other
molecules of interest. In chapter 3 there will be the discussion of “click” chemistry and
in chapter 6 there will be a discussion of nanoparticles that operate as T1 agents.
Therefore a deeper understanding of the Bloch equations is not needed to appreciate the
work presented in this thesis.

The acquisition of a T1-weighted image is enhanced by Gd3+ agents due to the short T1
relaxation rate of the water that interacts with the agent. A typical Gd3+ contrast agent on
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a 9.4 T MR scanner (400 MHz spectrometer) will have a relaxivity of 2-3 mM-1 s-1. This
means that for a sample having 1 mM CA agent the T1 will be 333 – 500 ms for the water
that interacts with the agent. While the assumption that all the water in a NMR tube
would interact with the agent, the same cannot be said for in vivo imaging. Different
tissues and different areas of a slice will not interact with an agent to the same extent.
Thus relaxation times will differ for different tissues types and concentrations of agent.
If a pulse sequence is designed accordingly, imaging only the quickly relaxing 1H nuclei
will be achieved, and slowly relaxing 1H nuclei will not be observed. To put this into
perspective, some T1 relaxation rates of tissues are listed in Table 1.1.

Table 1.1 T1 relaxation rates of 1H 2O for brain tissues at 4T.10
T1 (s)
White Matter

1.010

Grey Matter

1.723

Blood

1.914

Cerebrospinal fluid

4.472

Taking these values as averages for in vivo imaging, one can see that using a CA that has
an r1 of 2-3 mM-1 s-1 will change water’s T1 enough (300 – 500 ms) to generate a contrast
image. This however assumes that a 1 mM concentration is achieved in the region of
interest during imaging, which is not always possible. As the r1 of the contrast agent
increases the concentration needed to produce the same contrast decreases. Thus the
motivation for the development of new agents possessing increased relaxivity while
maintaining good stability in vivo. Figure 1.3 illustrates the origin of a MRI contrast
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enhancement in the presence of a T1 relaxation agent. The difference in the signal with
and without agent is used to generate the contrast in T1 weighted MR images.

Figure 1.3. Representation of the contrast that is realized by use of a T1 relaxation agent
vs. water without a relaxation agent. The solid curve is the signal intensity of water as a
function of time using an inversion recovery sequence with a relaxation agent. The
dashed curve is the signal intensity of as a function of time using an inversion recovery
sequence without a relaxation agent. T1 relaxation is faster for the system where a T1
agent is used. The difference in these two intensities allow for a contrast during T1
weighted MR imaging.

The evaluation of T1 agents is typically done by comparing the inverse of the T1 values
normalized to 1 mM and reported as relaxivity with units (mM-1 s-1). The inversion
recovery experiment is not a typical experiment for organic chemists and therefore will
be discussed briefly for clarity. The simplest way to discuss the inversion recovery
experiment is to visually represent how the magnetization (Mz) changes over time after a
“flip” of the angle.

Figure 1.4 has a representation of how the inversion recovery
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experiment is performed. Figure 1.5 has a representation of what occurs by arraying the
time before the 90° pulse is applied, along with a spectral representation of the signal.

Figure 1.4. Representation of an inversion recovery experiment. Firstly a 180° pulse is
applied causing the Mz to point along the –z axis. This is followed by arraying the time
before a 90° pulse is applied, which flips the magnetization along the -x followed by
detection.

Figure 1.5. Top. Representation of the magnetization after a 90° pulse is applied at
different time points. The time is arbitrary with the time 0 being the shortest and time 3
being the longest time. Bottom. Representation of the spectra after a 90° pulse is applied
at varying time points.
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As the time between the 180° and the 90° is delayed from time 0 to time 3 the signal
changes from being negative, (or along the –x axis), to a positive signal, (or along the +x
axis). When the intensities of the signal are plotted vs. time a T1 curve is produced, such
as that seen in figure 1.3. An exponential curve can then be fitted accordingly to the T1
relaxation equation.

1.2.2

T2-Based Contrast Agents

T2-based contrast agents are typically designed using superparamagnetic iron oxide
(SPIO) particles. The field inhomogeneity of SPIOs alters the magnetic field, which in
turns creates 1H nuclei of different frequencies and ultimately dephases the water signal
(Figure 1.6). By dephasing the water being imaged, a darkening, or negative contrast,
where the SPIOs are located is observed due to the signal loss of out of phase water. This
is the opposite of T1 agents that produce a brighter image (positive contrast). As no
SPIOs were synthesized and tested for this thesis the focus of T2 relaxation will be with
respect to a new form of T2 agents. Lanthanide based T2 agents have recently been
developed that rely on the field disturbance that high shifting lanthanides can produce.11
The same macrocyclic chelator cyclen is used in these agents, but instead of gadolinium
as in the T1 agents, lanthanides that produce large hyperfine shifts are used, such as,
dysprosium (Dy3+), thulium (Tm3+) or terbium (Tb3+). As an example of the high shifting
ability of lanthanides, the chemical shift of bound water on a Dy3+ ion has been observed
above 700 ppm compared to the bulk water.12 The difference in frequency of the bound
water compared to the bulk water creates a powerful T2 agent due to the dephasing that
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occurs when the bound water exchanges and interacts with the bulk system creating a
decrease in the overall water signal. T2 imaging is not a main focus of this thesis and will
only be discussed to any extent in chapter 5. It is however important to remember in all
MR imaging when lanthanides are present there is the possibility of increased T2
relaxation, which could ultimately decrease the amount of signal and effect the overall
efficiency of the agent.

Figure 1.6. Representation of water signal loss due to T2 relaxation. a) M0 is aligned
along z axis at equilibrium. b) After a Rf pulse flips the M0 vector onto the x axis. c)
Dephasing of the M0 signal on the xy plane resulting in a decrease in measurable signal.
Redrawn from reference 11

To measure the T2 relaxation of an agent a Carr-Purcell-Meiboom-Gill (CPMG) pulse is
used. Figure 1.7 has a representation of how a CPMG sequence can be used to measure
the T2 of an agent. In brief, after a 90° pulse the magnetization resides on the xy plane
(Fig 6 a). As discussed, the signal begins to dephase due to T2 relaxation. At a time
point (τx) (Fig 6 b), which can be arrayed, a 180° pulse is applied and the signal can be
measured with loss in signal due to T2 (Fig 6 c). After the 180° is applied the signals that
were out of phase begin to move back into phase and after another period of time τx, the
signal will be fully rephrased, but in the opposite direction on the xy plane (Fig 6 d). As
the signals are still precessing at their own frequencies they begin to dephase once again
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(fig 6 e). At this point (τy) another 180° pulse can be applied and the rephasing will begin
again (Fig 6 f). If an array of times (τn) are used and plotted vs. the amount of signal
measured an exponential decay is observed, which can be fit accordingly to the T2
equation.

Figure 1.7. a) Magnetization on the xy plane after a 90° pulse is applied. b) Dephasing
occurs due to field inhomogeneities. c) After time (τ) has elapsed a 180° pulse is applied
the signals begin to rephase. d) After time τ the signals are rephased in the opposite
direction. e) The signals continue to precess in the same direction and continue to
dephase for another time period (τy). f) Rephasing of the signals occurs and will be fully
rephased at time τy. Redrawn from reference 1.1

1.2.3

CEST and ParaCEST Based Contrast Agents

Chemical exchange saturation transfer (CEST) and paramagnetic chemical exchange
saturation transfer (ParaCEST) are relatively new techniques for creating MRI contrast.
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In this thesis no CEST agents were developed; however, the properties for ParaCEST
resemble those for CEST, with the exception that ParaCEST employs a paramagnetic
metal. CEST was first discussed by Balaban in 2000 as a potential technique to develop
contrast in MRI13 with ParaCEST being developed the following year.14 The contrast for
ParaCEST MR imaging is generated using exchangeable protons from amides, amine,
alcohols or bound water to a paramagnetic metal of choice. In short, the contrast will be
generated using the saturation of the “bound” protons, which then exchange with the
“bulk” water, carrying the saturation to the bulk water, resulting in a saturation of the
bulk water. For simplicity the bulk water is thought of as having a single frequency,
which is usually referenced to 0 ppm and the true frequency is not important as gradients
used in MRI will create new frequencies for every slice. The bound protons on a
diamagnetic CEST agent can be amides, amines or alcohols and will have a chemical
shift of roughly 3 - 5 ppm compared to the bulk water. In NMR terms this is the
difference of water being at ~ 4.8 ppm and the exchangeable protons being ~ 7- 10 ppm.
Barbituric acid was one of the first agents discussed as a possible CEST CA and is shown
in figure 1.8. By applying a saturation pulse only onto the exchangeable ring protons (∆ 5
ppm compared to bulk water) the bulk water signal decreased by 32%.13 While this result
was substantial for use as an in vitro agent, it should be noted that there are numerous
other exchangeable 1H nuceli in vivo resonating between 3 – 5 ppm compared to bulk
water. The other exchangeable 1H nuclei resemble the CEST CA of interest and will
complicate in vivo studies. Recent studies have been published where CEST is tested in
vivo with no CAs.15, 16
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Figure 1.8. Structure of barbituric acid as one of the first CAs agents tested for CEST
MRI. The two symmetrical exchangeable 1H nuclei on the ring are at 5 ppm compared
to bulk water.13 A CEST % of 32% was generated using a 64 mM concentration of the
agent.

It has been shown that when a paramagnetic metal is placed into a magnetic field there is
potential for a large chemical shift of the nearby atoms. This has previously been used in
structure elucidation by NMR. Typically a europium salt (Eu3+) would be added to a
complex structure, such as proteins, and the shifts observed would be from protons
interacting with the metal which would give information of structure and binding pockets
of the protein.17 Because of the unpaired electrons of Eu3+ not being symmetrically
distributed it creates large chemical shifts from the typical solution state proton NMR (0 15 ppm) to a wide range of chemical shifts (± 50 ppm). The size and magnitude of the
shift observed is dependent on distance, angle relative to the principal magnetic axis of
the system as the z-axis, and the paramagnetic metal. A representation of paramagnetic
properties for the lanthanides is shown in figure 1.9.
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Figure 1.9. Paramagnetic properties of the lanthanides: μeff is the calculated magnetic
moment based on the ground term; μB is the Bohr magneton PRE is the paramagnetic
relaxation enhancement, and the radius of the yellow sphere indicates the distance at
which 1H NMR signals experience significant line broadening. PCS is the pseudocontact
shift, and the isosurfaces represent the sign and magnitude of the lanthanide-induced
pseudocontact shift for each ion.18 Note that Eu3+ would theoretically be diamagnetic
according to its 7F0 ground state, but its magnetic properties are also influenced by
contributions from the low-lying, thermally accessible 7F1 and 7F2 levels giving rise to a
magnetic moment of around 3.5 μB. Adapted for reprint with permission from reference
19. Copyright 2013 American Chemical Society.18, 19

Figure 1.9 illustrates the relaxation sphere around the metal as well as the pseudo contact
shift of each metal.

While the relaxation sphere for gadolinium is large it has no

pseudocontact shift, for this reason gadolinium is used solely as a T1 agent. The rest of
the metals contain some combination of both relaxation as well as pseudo contact shift.
The large shifting agents (Dy, Tb, Ho, Er) have large pseudo contact shift values as well
as sizable relaxation efficiency.

For this reason these agents can be used as both

relaxation agents (T1, T2) as well as ParaCEST agents, where their chemical shifting
abilities are needed. Tm, Eu, and Yb all contain sizable pseudocontact shift values while
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their relaxation sphere is negligible. This allows these metals to be used as ParaCEST
agents without the problems of relaxation, which will be discussed in chapter 5.
The first ParaCEST agent to be discussed in the literature was a Eu3+ tetraglycinate by
Sherry and coworkers (Figure 1.10).14 This agent was constructed similarly to Gd3+ T1
agents in the sense that a cyclen framework was employed as a chelating agent for the
lanthanide with four “arms” with carbonyls to fill out four other chelating sites of the
lanthanide.

Figure 1.10. Chemical structure of Eu3+ tetraglycinate.

The difference in ParaCEST agents compared to T1 agents is the use of amides in place of
acids on the arms. This allows a slower exchange rate of the bound water, which is
required for ParaCEST imaging. To generate contrast in the ParaCEST technique a
saturation of exchangeable protons at a frequency away from the bulk system must be
done. When water is bound to Eu3+ there is a chemical shift of 50 ppm for the bound
water. With a chemical shift of 50 ppm, the bound water can be saturated without
affecting the bulk water, which is referenced to 0 ppm (Figure 1.11). However, because
the bound water is in exchange with the bulk water, the bound water must reside on the
metal long enough to be saturated with an Rf pulse. This is the reason why the acids of
the T1 agents have been replaced with amides for ParaCEST agents. Amides are weaker
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electron donors compared to carboxylates. When an amide is used there is an electron
deficiency on the lanthanide center creating a stronger OH2 interaction, ultimately
slowing water exchange. A second strategy for slowing water exchange is the
incorporation of sterically hindering side chains. Because water exchange has been
shown to be dissociative,20 a system that is sterically hindered will have less solvent
accessibility. This in turn limits the hydrogen bonding to bound water and slows water
exchange.21 With the incorporation of amides into the scaffold there is the potential for
other exchangeable 1H nuclei. If Eu3+ is replaced with other lanthanides (Dy3+, Tm3+,
Tb3+, Yb3+) the amide proton is shifted to values that can be can be saturated without
effecting bulk water (∆ω of amide -NH: Dy3+ ~ 70 ppm, Tm3+ ~ 50 ppm, Tb3+ ~ 60 ppm,
Yb3+ ~ 16 ppm). These values are dependent on the metal chosen, as well as the distance
and angle to the metal center. The values given here are average values seen in literature,
but there are exceptions which will be discussed in this thesis.

Figure 1.11. Schematic representations of the distribution of spins, aligned with and
against the field (upper and lower energy levels, respectively) (above) and simulated
NMR spectra (below) for two chemically distinct pools of nuclei (left), two spins after a
saturation pulse has been applied to one pool (middle), and for a system undergoing
chemical exchange after a saturation pulse has been applied to one pool (right).22
Reproduced with permission. Copyright 2013 American Chemical Society.
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The largest benefit of using ParaCEST agents over CEST agent is the large chemical
shifts of exchangeable protons, on ParaCEST agents, which allow for a direct saturation
at frequencies that will not interfere with bulk water. The second benefit of shifting the
exchangeable signal further away from the bulk water system is removal of the signal
from the magnetization transfer effect (MT).

The MT effect arises because of the

semisolid nature of biological tissues having a very short T2 value (< 1 ms).23 During the
ParaCEST imaging of in vivo systems the biological background noise ranges from ± 100
ppm, depending on saturation power used.23 Having an agent with an exchangeable 1H
nucleus that resonates outside of the MT will increase the signal to noise during in vivo
imaging.

The third benefit of having of using ParaCEST agents is the ability to either

turn “on” or turn “off” the ParaCEST agent.

nly when a saturation pulse is situated at

the frequency of the bound water or exchangeable amides 1H will there be saturation, any
other frequency will not affect the signal. This gives ParaCEST imaging the potential to
give unobstructed anatomical images directly before and after a ParaCEST image. This
feature is unlike T1 and T2 imaging as those agents are always “on” and will always affect
the image of nearby water. While typically lanthanides are used in ParaCEST there is
also the possibility of transition metals. So far paramagnetic iron and nickel have been
used and have been coined the terms FeCEST and NiCEST.24, 25 This thesis however will
focus on the lanthanide series of the 3+ states.
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1.2.4

Objectives of Research

The research focus of this thesis is the development and evaluation of novel contrast
agents for MR imaging.

When this research began ParCEST based contrast agent

development was in its infancy and thus held the opportunity to explore novel structures
for their MRI CA ability. Firstly, we were interested in exploring variations on the
DOTAM scaffold to investigate the ability to tune metal based water or ligand based
ParaCEST properties.

To this end a key intermediate, tetrapropargyl DOTAM was

synthesized and expanded upon via click chemistry.
Objective 1:

Determine the utility of click chemistry on tetrapropargyl

D TAM and discover interesting “lead” compounds for further development.

Through working with variations of the amide groups the click approach was replaced by
surveying structurally simple amides prepared by more traditional chemical approaches.
Objective 2: Determine the effect of structure variations, particularly steric
bulk of D TAM amides for ParaCEST properties to discover “lead”
compounds for further investigations.
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Surveying of DOTAM amides with varies alkyl substitutions led to the discovery of
compounds that produced unusually high chemical shifts and these were studied further.
Objective 3: To determine the ability of the newly discovered agents to
circumvent the limitation of in vivo use of ParaCEST agents due to MT
effects.

It was also discovered that the unusually high shifting signal was due to the presence of
the TSAP isomer. This led us to investigate other amides to determine if the TSAP
isomer could be favoured by variation of substitution.
Objective 4: Preparation and evaluate DOTAM analogues possessing anilides
for potential steric/electronic tuning of the electronic properties.

Finally, the question of pharmacokinetic distribution and detection was investigated for
nanoparticle based contrast agents.
Objective 5: Prepare and evaluate Gd NP-Gd3+ conjugates for their MR
imaging properties, and test their utility in biological imaging.

By focusing on the limitations of ParaCEST imaging, such as non specific
biodistribution, background MT effects and loss of sensitivity due to T2 shortening we
developed general strategies to increase the sensitivity of future ParaCEST agents.
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Chapter 2: Magnetic Resonance Spectroscopy Contrast
Agent for Temperature Measurements

“Contrast Agents Possessing High Temperature Sensitivity” Mark Milne, Robert
H. E. Hudson. Chem. Commun., 2011, 47, 32, 9194-9196.

2.1 Introduction

Noninvasive thermometric mapping has the opportunity to provide information on
physiological conditions of both abnormal and normal tissues. It may also be used to gain
real time information such as during thermal therapy that used in cancer treatment.1-3
Higher than normal temperatures have been reported during imaging of cancerous tissue,
a phenomenon which has been linked to an increase in the metabolism of glucose.4,

5

Determination of such temperature abnormalities is an important step in the early
detection of cancers.

Currently, temperatures within a biological system may be

monitored either invasively using an external probe or by noninvasive scanning
techniques. For instance, fiber optic probes are capable of monitoring temperature within
0.1°C; however, these need to be implanted which poses the risk of infection and acute
damage. Direct temperature sensing in this manner also relies on the probe being close to
the sample area of interest to ensure accuracy. Alternatively, there are a number of
noninvasive thermometry techniques such as T1/T2 relaxation measurements, diffusion
and magnetization transfer based techniques. These methods are limited in their ability to
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accurately determine absolute temperature within the short time frame needed for some
applications, such as thermal therapy.1 Temperature mapping of water alone has been
shown to be possible but suffers from a low sensitivity of 0.01 ppm/°C.

6

To overcome

the shortcoming of a low temperature coefficient (CT), lanthanide based contrast agents
have been developed with higher sensitivity to temperature and ultimately leading to
shorter acquisition times. Most notable are YbDOTMA-,7 Pr[MOE-DO3A],8-10
TmDOTMA- 11-15 and TmDOTP5-, Figure 2.1.11, 16-18

Figure 2.1: Structures of Ln3+ chelates used as temperature responsive agents.

YbDOTMA- was one of the first magnetic resonance spectroscopy (MRS) agents
developed; however, it possesses a relatively low CT value (0.04 ppm/°C). Subsequently
more sensitive agents were discovered. Pr[MOE-DO3A] possesses a CT value
approximately 10 times greater than water (0.131 ppm/°C). Testing of this agent has
shown that absolute temperature mapping should be possible for lanthanide DOTA like
agents9 and has led to the development of even more sensitive agents. The phosphonate
methylene protons of TmDOTP5- show a greater sensitivity with a CT value of 0.87
ppm/°C. To its detriment, this agent also responds to both pH and [Ca2+] which interfere
with the absolute temperature determination.11,

16 17

TmDOTMA- has a CT of 0.57

ppm/°C for the 12 equivalent hydrogens and a shift of nearly -100 ppm at 35°C.
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Although the CT of this chelate is nearly 60 times that of water alone, it exists as two
isomers in solution; a common phenomenon for cyclen-based contrast agents.
TmDOTMA- exhibits both the monocapped twisted square antiprismatic (TSAP) and
monocapped square antiprismatic (SAP) in solution.19

The TSAP conformer

predominates (93%) and its methyl signal alone is used for measurements.12

2.2 Results and Discussion

A series of new agents for potential temperature mapping have been developed that show
high sensitivity, exist as a single isomer and produce high chemical shifts. Using
tetrapropargyl amide derivatized cyclen (2.1) as the chelating ligand,20 a series of
complexes was evaluated for their ability to report temperature by using the H4 or H5
protons, Figure 2.2. The chemical shifts of H4 and H5 are independent of either
concentration, pH or [Ca2+]12, 13 which is important because of the uncertainty of these
factors in vivo without pre scanning with other contrast agents.

Figure 2.2. Ln chelates were prepared by treatment of ligand 1 with 1.1 eq of appropriate
a 1:1 mixture of dioxane:H2O. Protons denoted as H1-H6 ,CH2 p (propargylic) and Ht for
the terminal alkyne proton.
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While the complexes of DOTMA show significant amounts of a minor isomer (Tm3+,
7%; Tb3+, 30%), conformational analysis by solution NMR along with solid state
structures determined by single crystal x-ray diffraction show only the SAP isomer
present in complexes of 2.1. This is advantageous because the entire signal can be used
in determining the peak position thereby improving the signal to noise ratio (SNR). The
H4 peak position of Eu3+ complexes of cyclen-like ligands may be used to distinguish
between the TSAP and SAP conformers in solution. The chemical shift of H4 falls
between 8-10 ppm for the TSAP conformation while the signal is near 30 ppm for the
SAP conformation19, 21 Eu(2.1) has a peak near 25 ppm, Figure 2.3, indicative of the SAP
conformation. The SAP conformation was observed in the crystal structure reported
earlier for a Gd3+ tetrapropargyl complex,22 as well as the crystals that we obtained for
other Ln3+(2.1) complexes.23

Figure 2.3. NMR spectra of Eu(2.1) in D2O. The signal for H4 is observed at ~25 ppm,
indicated by the arrowhead
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To evaluate the ability of these contrast agents to report temperature, we selected
lanthanides capable of producing large hyperfine shifts (Tm3+, Tb3+, Dy3+). Complexes of
Tm3+, Tb3+, and Dy3+ have been tested in the past for their ability to report temperature
because of their high CT values (0.131 ppm/°C to 2.18 ppm/°C)13 compared to water 0.01
ppm/°C. Plots of temperature versus peak position for Tm(2.1) are shown in Figures 2.4
and 2.5. Linear fit values for tested agents are (Tm(2.1)H4 R2 = 0.983, Tm(2.1)H5 R2 =
0.993, Dy(2.1) H4 R2 = 0.997, Tb(2.1)H4 R2 = 0.999).
.
40 °C
39 °C
38 °C
37 °C
36 °C
35 °C

Figure 2.4. Temperature dependence of the H5 NMR signal of Tm(2.1) in the range 3540°C. See supplemental information for full listing of parameters.

A summary of the evaluation of the three most promising agents: Tm(2.1), Tb(2.1) and
Dy(2.1), is listed in Table 2.1. The CT values range from -1.05 ppm/°C for the H5 of
Tm(2.1) to 1.76 ppm/°C for the H4 of Dy(2.1). These values represent a substantial
improvement over the state of the art compounds. The temperature sensitivity of the
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ligand proton signals of these compounds is ~100 more sensitive then water alone and 23 times greater than reported TmDOTMA and it is not sensitive to pH within the
physiological range. CT values alone however are not sufficient to represent which
agents will be most useful. The ratio of the line width at half maximum (FWHM) to CT
ratio is a good indicator of the effectiveness of the complex as a temperature reporting
agent and is a value that permits comparison to other agents. The highly-shifted signals
appearing at -333 ppm (Dy(2.1)H4), -287 ppm (Tb(2.1)H4), 224 ppm (Tm(2.1)H4) and 148 ppm (Tm(2.1)H5) show the largest variation with respect to changes in temperature
and were the ones exploited for the measurements reported.

Figure 2.5. Temperature vs. chemical shift for Tm(2.1) H4 (▲) and H5 (■).
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Table 2.1. 1H Chemical shifts (ppm) at 35 °C, temperature coefficients, line widths at half
max height and T1 for Ln3+(2.1) complexes at 20 mM
Tb3+ (H4)

Tm3+ (H4)

Tm3+ (H5)

Dy3+ (H4)

δ (ppm)

-287.13

224.52

-148.25

-332.98

CT (ppm/°C)

1.48

-1.44

1.05

1.76

FWHM

1.25

0.80

0.64

1.41

|CT|/FWHM

1.18

1.80

1.64

1.25

T1 (msec)

0.39

0.64

0.95

0.29

Ratios of │CT │/ FWHM between 1.0 - 2.2 have been reported; however, the highest
value corresponds to a compound that is sensitive to both pH and [Ca] which is
problematic for in vivo use where these values are variable. Dy(2.1) with a CT value of
1.78 ppm/°C and a line width of 1.41 ppm has a ratio of 1.25. This value is comparable to
other complexes used for imaging, (1.18 for TmDOTA- and 1.36 for TmDOTMA-).11, 13,
24-26

The ratio values obtained for the other two complexes are 1.18 and 1.66 for Tb(2.1)

and Tm(2.1) H4 protons, respectively, and 1.64 for H5 of the Tm(2.1) complex. The Tm3+
complex benefits from a narrow peak width (0.84 ppm for H4 and 0.64 ppm for H5) and is
therefore more suitable for temperature mapping while still displaying high temperature
dependence.
To further evaluate Tm(2.1), a 20 mM sample was prepared in a 5% w/v denatured
bovine serum albumin (BSA) gel. 1H NMR spectra were collected under similar
conditions to the calibration samples with the exception that the scan time was reduced
from 100 scans (3 min) to 16 scans (34 s), which is closer to the time for a single breath
hold for imaging purposes. The CT values determined under these conditions were -1.33
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(ppm/°C) for the H4 proton and 0.90 (ppm/°C) for the H5 proton.

Using the high

chemical shifting signals provides large changes with respect to temperature and also
ensures they are free of signal interference from proteins (in the BSA scans) or other
endogenous biomolecules. It is also expected that no exchange will occur between the
protons of the cyclen backbone, therefore line broadening should not be a concern for in
vivo use and only minimal line broadening was observed in the BSA studies. The slight
increase in half line width is most likely due to the decrease in scans used in the BSA
studies to demonstrate the potential of Tm(2.1) in a biological medium. The results
indicate that we are able to perform the same temperature determination under pseudobiological conditions with short scan times. With two proton signals for Tm3+ clearly
outside the range of biological background signals, it should be possible to measure both
H4 and H5 and use the shift of both peaks to yielding a sensitivity of 2.38 ppm/°C, as
previously proposed.26

2.3 Conclusion

In summary, a series of contrast agents have been identified that are potential candidates
for MR thermometry. The presence of one conformational isomer in solution enables the
use of the entire signal to determine the peak position. By showing that similar results
can be obtained in pseudo-biological conditions we have demonstrated the compatibility
of these agents to biological applications. Cell viability tests have been performed by
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others indicating that at concentrations below 3 mM the contrast agent is non toxic,
which will allow in vivo testing to be preformed.22

Since the publication of this paper in 2011 we were contacted by the National Institute of
Standards and Technology. They believe that the Tm3+ agent has the potential to act as a
standard for temperature controls during NMR experiments. We have prepared samples
for testing and are awaiting the results of their evaluation.
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2.4 Supplemental information
S2.1. 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-N-(propargyl)acetamide (2.1)
To a stirred solution of cyclen (38 mg, 0.22 mmol) and DIPEA (154 µL, 4 mmol) in 5
mL acetonitrile, N-(propargyl) chloroacetamide (6) (131 mg, 1 mmol) was added in one
portion and then refluxed overnight. The product was precipitated with 5 mL H2O and
filtered as a white solid (66 mg, 0.11 mmol), yield 54%. 1H NMR (400 MHz, DMSO-d6):
δ 7.57 (4H, m); 3.05 (8H, m); 2.22 (10H, m); 1.79 (14H, s); 1.67 (4H, s,). ESI-m/z calc
C28H40N8O4 (M+H)+,553.3251, found 553.2574.

S2.2.

Ln3+-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-N-(propargyl)acetamide

Chloride (Ln(2.1))
Tetrapropargyl DOTAM (2.1) (55 mg, 0.1 mmol) was added to a stirred solution of
dioxane:H2O (4 mL) containing one of the following lanthanides at 1.1 eq: TbCl3, DyCl3,
TmCl3. The progress of the metallation of 2.1 was monitored by UPLC/MS and upon
completion the solvent was removed under reduced pressure. The solid was then taken in
1 mL H2O and passed through a column of size exclusion gel. The fractions collected
were tested against xylenol orange for the presence of free metals. Fractions identified as
containing the metallated ligand were found not to contain free metal ions. ESI-m/z:
C28H40N8O4Tb

(M+COOH)+,

calc

757.2481,

found

757.3318;

C28H40N8O4Dy

(M+COOH)+, calc 756.2627, found 756.3125; C28H40N8O4Tm (M+COOH)+, calc
767.2570, found 767.3286.
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S2.3. Temperature vs. δ (ppm) Dy(2.1) H4

S2.4. Temperature vs. δ (ppm) Tb(2.1) H4
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S2.5. Temperature vs. δ (ppm) Tm(2.1) H4

S2.6. Temperature vs. δ (ppm) Tm(2.1) H5
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S2.7. Temperature vs. δ (ppm) Tm(2.1) H4 , H5 in 5% BSA

S2.8. δ ppm vs. pH of Tm(2.1)
Table.  (ppm) vs. pH of Tm(2.1) H5
pH

ppm

6.00

-144.99

6.98

-144.94

8.22

-144.92

9.22

-145.10

39

S2.9. NMR Parameters
The NMR experiments were preformed on a 600 MHz Varian vertical bore magnet. 1H
experiments of Ln3+ complexes were done in deuterated water. Temperature dependence
studies were done in distilled water using the variable temperature (VT) control supplied,
which was first calibrated using glycol. Temperature calibration experiments of Ln
complexes were done at 20 mM in a range of 35˚C – 40˚C in triplicate and averaged.
Parameters used, 100 scans, Tm: Relaxation delay = 0.8 sec, observed pulse = 20˚, sweep
width = -170 to 250 ppm, acquisition time = 1.0 sec, overall time = 3:05. Tb: Relaxation
delay = 0.8 sec, observed pulse = 20˚, sweep width = -325 to 250 ppm, acquisition time =
0.76 sec, overall time = 2:41. Dy: Relaxation delay = 0.8 sec, observed pulse = 20˚,
sweep width = -250 to 150 ppm, acquisition time = 0.9 sec, overall time = 2:55.

Parameters used in 5% BSA study, 16 scans, Tm: Relaxation delay = 0.8 sec, observed
pulse = 20˚, sweep width = -170 to 250 ppm, acquisition time = 1.0 sec, overall time = 34
s. FIDs were then line broadened 30 Hz, phased corrected and baseline subtracted.
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Chapter 3: Synthesis and Characterization of ParaCEST
MRI Agents via Click Chemistry

“ParaCEST MRI Contrast Agents Capable of Derivatization via ‘Click
Chemistry’ ”. Mark Milne, Kirby Chicas, Alex Li, Robert Bartha and Robert H.E.
Hudson. Org. Biomol. Chem., 2012, 10, 287-292.

3.1 Introduction

Cyclen-based chelates of lanthanide ions, particularly gadolinium although other metals
are being actively investigated, are widely used as contrast agents in magnetic resonance
imaging (MRI). These agents rely on the exchange of water between the bulk and the
coordination sphere of the lanthanide.1-7 The exchange rate of bound water depends both
on the nature of the ligand and the identity of the metal ion. The exchange rate of bound
water has been described as fast in 1,4,7,10-tetrakis(carboxymethy1)-1,4,7,10tetraazacyclododecane (DOTA) type ligands, or slow to intermediate, as in 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetamide (DOTAM) type ligands. Due to these two
possible exchange rate regimes, two different techniques have been developed to create
contrast in MRI. Fast exchange occurs when Gd3+ is used in combination with DOTA
type ligands wherein the change in T1 is used to produce the contrast. Alternatively,
contrast agents in the slow to intermediate exchange regime, such as the combination of
DOTAM type ligands and Eu3+, use paramagnetic chemical exchange saturation transfer
(ParaCEST) phenomenon to produce contrast. Not only does the exchange rate depend
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on the gross chemical features of the ligand, it is also sensitive to the geometry of the
chelator about the metal centre. It has been described that cyclen-based contrast agents
are found in either a twisted square antiprismatic (TSAP) form, in which exchange is fast,
or in a square antiprismatic (SAP) form in which the exchange is slower.2, 6-10 In order to
maximize the ParaCEST signal, it is desirable to have ligands which exist only in the
SAP geometry.
Development of targeted contrast agents using glycoconjugates have been studied
recently. A number of different synthetic approaches have been investigated producing
contrast agents ranging from those possessing a single saccharide up to dendrimeric
structures containing twelve glucose moieties.11-14 Most of these agents have relied on
Gd3+ to produce contrast using the theory of relaxivity as previously discussed. The use
of other lanthanides which produce large chemical shifts suitable for use in ParaCEST
experiments have not been exploited to the same extent. By incorporating metal ions that
are compatible with the ParaCEST approach, we are able to measure the metal-bound
water of Eu3+ complexes, as well as the exchangeable amide protons in the other
lanthanide complexes (especially Dy3+, Tm3+ and Tb3+). The latter group of lanthanides
have elicited interest lately due to the sensitivity of amide proton exchange to changes in
pH and the potential for in vivo, non-invasive pH measurement. The potential for the
measurement of physiological parameters, such is pH, is one of the advantages of
ParaCEST agents over conventional T1 agents. Determination of in vivo pH has
implications for the early detection of cancerous tissue which is known to be acidic
compared to healthy tissue.15, 16 A second benefit of using the signal from exchangeable
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amide protons is the increased CEST sensitivity compared to bound water due to the
greater number of equivalent protons, provided that the contrast agent is symmetrical.17

3.2 Results and Discussion

A recent publication18 on related compounds has prompted us to report our ongoing
studies on the structure and properties of a tetraalkyne DOTAM series of lanthanide
complexes toward the development of new contrast agents.19

The synthesis of

tetraalkyne DOTAM was prepared by a modification of a literature procedure (Scheme
3.1).20

Scheme 3.1. Synthesis of Ln 3.1

Complexation of the lanthanide metal series was carried out by adding 1.1 eq of
appropriate LnCl3 ( Ln3+ = Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb) to the
tetraalkyne DOTAM ligand (3.1) in 2 mL of a 1:1 mixture of dioxane:H2O followed by
overnight stirring. The solvent was evaporated and the solids were taken up in 1 mL H2O
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and passed through a column of size exclusion gel to remove free Ln3+ ions which was
confirmed by the xylenol orange test.

The solvent was evaporated to yield Ln3+

complexes. Conformational analysis was done by solution 1H NMR, Figure 3.1 and
Table 3.1 The signal at ~25 ppm (Eu-3.1) is characteristic of SAP geometry and the lack
of a signal at 8-10 ppm indicates the absence of the TSAP isomer in solution. The
solution phase NMR data taken together with solid state X-ray crystal structures (Nd-3.1,
Tb-3.1, Dy-3.1, Yb-3.1, Figure 3.2), indicate that only the SAP isomer is present for the
lanthanide series of tetraalkyne DOTAM.

a)

b)

Figure 3.1. a) 1H NMR spectra of Eu-3.1. H4 indicated by arrowhead. b) Designation of
ligand hydrogen atoms (H1-H6) present in the Ln-3.1 complexes.
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Table 3.1 1H NMR chemical shifts (ppm) at 25˚C for the Ln3+ series.
Ln
Ce3+

H1
6.71

H2
1.66

H3
0.75

Pr3+

14.09

3.22

0.79

-22.65

Nd3+

10.61

5.62

5.02

3+

Sm

H4 H H5
-7.58
7.45

H6
5.17

CH2
4.97

CH
4.97

16.99

10.76

6.69

3.82

-11.38

12.34

5.62

7.46

5.48

4.39

1.61

1.79

-0.02

5.93

3.72

4.30

2.79

3+

-9.58

-2.98

-4.98

24.43

-12.76

-8.83

2.57

1.53

Tb3+

104.74

-80.15 -83.30 -310.02

202.11

57.05

35.58/30.82

19.61

Dy3+

123.52

-83.04 -83.04 -356.08

234.87

77.18

38.76/33.88

22.04

Ho3+

65.27

-47.36 -43.19 -181.61

122.53

35.31

22.17/19.55

12.55

Er3+

-2.50

-2.82

Eu

-34.82

2.20

11.69

106.08

-61.37

-39.64

3+

-85.88

30.33

40.30

247.40

-156.17

-74.56

Yb3+

-30.64

14.19

17.14

94.09

-55.40

-25.15

Tm

-12.18/-13.22
-2.23

-9.87
-2.58

α)

Figure 3.2. Left: Top down view of a molecular representation of the crystal structure of
Dy-3.1. α indicates the angle between the planes created by N-Ln-N and O-Ln-O and are
listed in Table 2. Right: side on view showing water coordinated to the metal centre, the
positions of hydrogen atoms were not determined experimentally and are omitted for
clarity.
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The lanthanide tetraalkyne DOTAM complexes possess nonplanar conformations with
C4 symmetry which can be identified by the presence of 8 proton signals, denoted H1 to
H6, CH2 (propargylic methylene) and CH (terminal proton). Those protons closer to the
metal centre exhibit higher chemical shifts than in the free ligand due to the magnetic
moment of the metal centres (Table 3.1).21 Of note, the protons for the CH2 group for
Dy3+, Ho3+, Tb3+ and Tm3+ compounds show two separate peaks, where the rest of the
metals show a single peak. This is likely due to the large shift capabilities of these four
compounds resolving the diastereotopic protons. Proton analysis was not performed for
the Gd-3.1 complex due to line broadening.
These results are notable, particularly, when compared to other high chemical shift
lanthanide complexes which have shown two isomers in solution.8 The SAP isomer is
desirable for two reasons: firstly, it produces greater hyperfine shifts of the ligand
(cyclen) associated protons that may be useful for magnetic resonance spectroscopic
applications. Secondly, the SAP isomer has the slower water exchange rate of the two
isomers and this feature is important for ParaCEST-based contrast agents.
To illustrate the competence of the DOTAM alkyne to be derivatized, we have taken
tetraacetylglucosyl propylazide and performed a copper-catalyzed azide-alkyne 1,3
dipolar cycloaddition (CuACC) or “click”22 reaction to give a tetra glucose (OAc)4.23
This chemistry was performed on a series of pre-metallated ligand (Ln-3.1, Ln = Eu3+,
Dy3+, Tm3+, Tb3+, Gd3+) to avoid metal sequestration by the naked ligand and subsequent
need for transmetallation.

48

The acetyl-protected glucose intermediates Ln-3.2 were purified by HPLC, isolated in
60-82% yield, and their identities were confirmed by high resolution mass spectrometry.
The glucose moieties were deacetylated using a catalytic amount of potassium carbonate
in methanol and this reaction was subsequently quenched by stirring with Amberlite 120
resin. This treatment afforded the fully deprotected tetraglucoside (Ln-3.3) products in
high yield (99 %), (Scheme 3.2).
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Scheme 3.2. Synthesis of a tetraglucoside functionalized DOTAM via the acetylprotected intermediate by Huisgen copper catalyzed alkyne-azide cycloaddition
(CuAAC).
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A selection of lanthanides was used in the click reactions based on their potential as
contrast agents. Gd3+ was chosen for its ability as a T1 relaxation agent while the other
lanthanides (Eu3+, Dy3+, Tb3+, Tm3+) were chosen because of their favourable
characteristics as ParaCEST contrast agents.
To evaluate the series of complexes as potential contrast agents for MRI, relaxation
measurements and CEST experiments were made. NMRD profiles were acquired at
25°C using a STELLAR fast field cycling NMR. CEST spectra were acquired at 25°C, at
10 mM in phosphate buffer (pH 7) and show observable signals due to bound water and
amide protons.
The measured r1 value at 20 MHz for Gd-3.1was 2.53 mM-1 s-1, which is comparable to
the value previously reported for Gd3+-DOTAM (2.5 mM-1 s-1).6 The relaxivity of the
products of the “click” reaction: the tetrakis(tetra-Oacetylglycoside) Gd-3.2 and the
deprotected agent Gd-3.3 were also evaluated. (Table 3.2) A value of 1.96 mM-1 s-1 at 20
MHz, 25°C was obtained for Gd-3.2 while a slightly higher value of 2.08 mM-1 s-1 was
obtained for the deacetylated compound Gd-3.3. The relaxivity measured at 400 MHz
was similar in that Gd-3.1 was the greatest with a value of 2.22 mM-1 s-1 while there was
a decrease for Gd-3.2 (1.96 mM-1 s-1) and an increase in Gd-3.3 (2.13 mM-1 s-1)
compared to Gd-3.2. This pattern is somewhat surprising when considering the size
difference between these three compounds.

Relaxivity theory states that as the size

increases so should the rotational time, ultimately giving rise to an increase in
relaxivity.24 This however is not the pattern observed for the Gd series. Gd-3.2 is
roughly 3 times larger than Gd-3.1 but a decrease in relaxivity of 12% is measured. This
unique situation is also shown in the change between Gd-3.2 to Gd-3.3 where relaxivity
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increases 8% while the size decreases by 27%. This can be explained by assuming that
the rotational time is not the leading factor associated with the relaxivity but instead
water exchange rate or accessibility to bulk water is more important in the slowintermediate exchange regime of DOTAM ligands.

The dependence on water accessibility can also be seen in the CEST experiments for both
the bound water of Eu series as well as the exchanging amide of the Tm series. CEST
experiments were performed on complexes (Eu-(3.1-3.3), Tb-(3.1-3.3), Tm-(3.1-3.3),
Dy-(3.1-3.3)) to evaluate their potential to act as ParaCEST contrast agents, Figure 3.3
and Tables 3 and 4. The high shifting lanthanides show CEST signals associated with the
exchangeable amide protons with results between 14 % (Tb-3.1, Dy-3.1) and 16 %, (Tm3.1). Exchangeable, metal coordinated water is observed for Dy-3.1 (4.4%), Tb-3.1
(5.4%) and Eu-3.1 (40%). By increasing the hydrophobic nature of the agents Eu-2 and
Tm-2, the CEST responses decrease to 18% for Eu-3.2 (H2O) and 2% for Tm-3.2
(amide). After deprotection of the glucose there is then an increase of 5% and 4%
observed for Eu-3.3 and Tm-3.3 respectively. This may be explained by the accessibility
of bulk water to exchange with the bound water or the amides in these systems where the
acetylated glucose possesses a greater barrier of accessibility for bulk water compared to
the deacetylated, which in turn is greater than the parent Ln-3.1 complexes. Because
DOTAM based contrast agents are in a slow-intermediate exchange regime the CEST
response and the relaxivity are both responsive to the hydrophibicity of the agents and
less responsive to the size change and rotational time. The CEST signals Dy-(3.2,3.3)
and Tm-(3.2,3.3) were not observed for both amide and bound water.
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Figure 3.3. CEST spectra acquired using parameters, 10 mM, 25 ˚C, 15 µT saturation
pulse for 4 seconds. a) Eu-3.1 b) Eu-3.2 c) Eu-3.3. Peak position and intensities are
listed in tables 3.3 and 3.4.

Table 3.2. Relaxivities of Gd3+ complexes ( mM-1 s-1)
Ln3+
r1(20 MHz)
r1(400 MHz)
Gd-1
2.53
2.22
Gd-2

1.96

1.96

Gd-3

2.08

2.13

Table 3.3. Chemical shifts and CEST signals of exchangeable amides
Ln3+
Dy-3.1

δ (ppm) amide CEST (%) amide
81
14

Tb-3.1

65

14

Tm-3.1

-54

16

Tm-3.2

-49

2

Tm-3.3

-51

6
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Table 3.4. Chemical shifts and CEST signals of bound water
Ln3+
δ (ppm) H2O
CEST (%) H2O
Dy-3.1
-765
4.4
Tb-3.1

-640

5.4

Eu-3.1

51

40

Eu-3.2

52

18

Eu-3.3

53

23

Crystals suitable for X-ray diffraction were grown by slow diffusion of acetone into a
concentrated aqueous solution of the complexes. All of the crystal structures displayed
nine-fold coordination of the metal centre consisting of four nitrogens from cyclen, four
oxygens from the pendant arms, and the last coordination site occupied by a single water
molecule of varying bond length (Nd = 2.47 Å , Tb = 2.44 Å , Dy = 2.43 Å , Yb = 2.42
Å). The angle between the planes of N-Ln-N and O-Ln-O was found to be between 3739˚ for all crystals, indicating a SAP geometry in the solid state. Selected bond lengths
and angles are summarized in Table 3.5 and are comparable to previously reported
similar DOTAM crystals.18 N-Ln distances of ~ 2.65 Å and O-Ln distances of 2.35 Å are
comparable to previously reported Gd DOTA crystals.25
summarized in Table 8.

Crystallography data is
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Table 3.5. Summary of torsion angle of pendent arms α (˚) and key bond lengths (Å)
α angle

Nd-3.1
37.48

Tb-3.1
38.94

Dy-3.1
39.04

Yb-3.1
39.51

N2-C-C-O1

22.8

35.1

30.0

22.9

N3-C-C-O2

35.8

30.1

28.3

34.0

N5-C-C-O3

28.3

28.4

23.3

30.1

N7-C-C-O4

30.7

23.2

34.6

28.3

N2-Ln

2.70

2.65

2.64

2.60

N3-Ln

2.70

2.65

2.60

2.62

N5-Ln

2.72

2.61

2.63

2.61

N7-Ln

2.66

2.64

2.64

2.57

O1-Ln

2.43

2.36

2.35

2.30

O2-Ln

2.48

2.36

2.41

2.30

O3-Ln

2.41

2.36

2.35

2.36

O4-Ln

2.45

2.42

2.35

2.36

H2O-Ln

2.47

2.44

2.43

2.42

CEST spectra were acquired on a 9.4 T scanner with the following parameters, FOV
(field of view): 25.6 x 25.6 mm2, matrix 128 x 128, flash pulse, TR: 6ms, TE: 3 ms, flip
angle: 6 degrees. The bound water paraCEST spectra for Eu3+, Tb3+ and Dy3+ was
acquired by applying a presaturation pulse at 15 µT for 4 seconds in steps of 5 ppm from
-1000 to 1000 ppm. Amide exchange spectra (Tb3+, Tm3+ and Dy3+) were acquired by
applying a presaturation pulse at 15 µT for 4 seconds in steps of 1 ppm from -100 to 100
ppm. All solvents were HPLC grade and used as such, except for dioxane and CH2Cl2
(dried by passing through columns of activated Al2O3) and water (18.2 MΩcm-1
deionized). Organic extracts were dried with Na2SO4 and solvents were removed under
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reduced pressure in a rotary evaporator. Size exclusion chromatography was carried out
on BIO-GEL P2, 45-90 mesh resin (20 g, column size 15 × 2 cm per 0.1 mmol of
compound). HPLC analysis was carried out using a high performance liquid
chromatograph using a Microsorb-CN column (particle size 5 µm; 4.6 id×200 mm).
Mobile phase: Gradient: 80:20 H2O:CH3CN to 35:65 H2O:CH3CN over 8 min 35:65
H2O:CH3CN for 7 min. Ln-3.2 (Rt =7.55 min). Ln-3.3 (Rt =1.50 min) NMR spectra
were recorded on a 400 MHz spectrometer; for 1H (400 MHz), chemical shift values (δ
are reported relative to TMS and were referenced to the residual proton in the deuterated
solvents as follows: CDCl3 (7.26 ppm); DMSO-d6 (2.49 ppm); D2O (4.75 ppm). Mass
spectra (MS) were obtained using electrospray ionization (ESI).

2-chloro-N-(propargyl)acetamide
Chloroacetyl chloride (5.97 ml, 75 mmol) was added dropwise to a stirred solution of
propargylamine HCl. (455 mg, 50 mmol) and NaHCO3 (12.75 g, 150 mmol) in 50 mL
dry DCM. The solution was stirred for 3h, filtered and washed with 5% NaHCO3. The
organic layer was dried over MgSO4 and dried under reduced pressure giving a brown
solid (3.52 g, 27 mmol), yield 54%. 1H NMR (400 MHz, CDCl3): δ 6.81 (1H, br, s); 4.01
(2H, s); 4.10 (2H, m); 4.07 (2H, s); 2.28 (1H, t, J = 2.5 Hz).

1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-N-(propargyl)acetamide (3.1)
To a stirred solution of cyclen (267 mg, 1.5 mmol) and DIPEA (955 µl, 24.8 mmol) in 10
mL acetonitrile, N-(propargyl) chloroacetamide (816 mg, 6.2 mmol) was added in one
portion and then refluxed overnight. The product was precipitated by the addition of 50
mL H2O and isolated by filtration. White solid (680 mg, 1.2 mmol), yield 76%. 1H NMR
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(400 MHz, DMSO-d6): δ 7.57 (4H, m); 3.05 (8H, m); 2.22 (10H, m); 1.79 (14H, s); 1.67
(4H, s,). ESI-TOF. m/z calcd for C28H40N8O4 (M+H)+, 553.3251, found 553.2574.

Ln3+-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-N-(propargyl)Acetamide
chloride (Ln-3.1)
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-N-(propargyl)acetamide (3.1) (55 mg, 0.1
mmol) was added to a stirring solution of dioxane:H2O (4 mL) containing one of the
following lanthanides at 1.1eq: CeCl3, PrCl3, NdCl3, TbCl3, SmCl3, EuCl3, GdCl3, DyCl3,
HoCl3, ErCl3, TmCl3, YbCl3.

Metallation was monitored by UPLC/MS and upon

completion was dried under reduced pressure.

ESI-TOF. m/z

C28H40N8O4Ce

(M+COOH)+, calcd for 736.2455, found 736.2704. C28H40N8O4Pr (M+COOH)+ calcd
for 737.2147, found 737.2833. C28H40N8O4Nd (M+COOH)+, calcd for 742.2461, found
742.2865. C28H40N8O4Tb (M+COOH)+, calcd for
C28H40N8O4Sm (M+COOH)+, calcd for

757.2481, found 757.3318.

749.2346, found 749.1833. C28H40N8O4Eu

+

(M+COOH) , calcd for 749.2426, found 749.1849. C28H40N8O4Gd (M+COOH)+, calcd
for 752.2582, found 752.3073. C28H40N8O4Dy (M+COOH)+, calcd for 756.2627, found
756.3125. C28H40N8O4Ho (M+COOH)+, calcd for 763.2531, found 763.3088.
C28H40N8O4Er (M+COOH)+, calcd for

762.2672, found 762.3002. C28H40N8O4Tm

(M+COOH)+, calcd for 767.2570, found 767.3286. C28H40N8O4Yb (M+COOH)+, calcd
for 768.2723, found 768.3187.

Ln3+-(1,4,7,10-tetraazacyclododecane-1,4,7,10)tetrakis(N-((1-(3-β-D-tetra(-Oacetyl)gluco)pyranodiyl)propyl)-1H-1,2,3-triazol-4-yl)methylacetamide

chloride

(3.2)
General synthesis of Ln-2 (Ln = Gd3+, Eu3+, Dy3+, Tb3+, Tm3+) Gd-1 (40 mg, 0.057 mol)
was dissolved in 2 mL 1:1 H2O:isopropanol and tetra-Oacetylglucosyl propylazide (147
mg, 0.34 mol, 6 eq) was added in one portion. Copper sulphate (0.03 mol) and sodium
ascorbate (0.06 mol) was added under an atmosphere of nitrogen and the mixture was
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stirred overnight. The product was isolated by HPLC to yield 113 mg (yield = 82%) of a
colourless solid. ESI-TOF: m/z calcd for C96H140N20O44Gd (M+H)+, 2431.8559, found
2431.8442. calcd for C96H140N20O44Tb (M+H)+, 2438.8821, found 2438.6610. calcd for
C96H140N20O44Dy (M+H)+, 2443.8933, found 2443.7889. calcd for C96H140N20O44Eu
(M+H)+, 2427.8531, found 2427.6267.

calcd for

C96H140N20O44Tm (M+H)+,

2445.8675, found 2445.6516.

Ln3+-Deprotection of 2 to give (1,4,7,10-tetraazacyclododecane-1,4,7,10)tetrakis(N((1-(3-β-D-gluco)pyranodiyl)propyl)-1H-1,2,3-triazol-4-yl)methylacetamide chloride
(3.3)
General synthesis of Ln-3 (Ln = Gd3+, Eu3+, Dy3+, Tb3+, Tm3+). Deprotection of
compound Gd-3.2 was done by addition of catalytic amount of K2CO3 (5 mg) to 50 mg
(0.02 mmol) DOTAM glucose click in methanol. The reaction was stirred 1.5 hr and then
Amberlite 120 resin was then added and mixture was stirred for an additional 30 min.
The solvent was filtered and dried to yield 35 mg (yield 99 %) of deacetylated complex
Gd-3. ESI-TOF: m/z calcd for C64H108N20O28Gd (M+H)+, 1759.6868, found 1759.6890.
calcd for

C64H108N20O28Tb (M+H)+, 1764.6974, found 1764.7158. calcd for

C64H108N20O28Dy (M+H)+, 1768.6934, found 1768.7091. calcd for C64H108N20O28Eu
(M+H)+, 1757.6854, found 1757.6976. calcd for C64H108N20O28Tm (M+H)+, 1773.6984,
found 1773.6870.

3.3 Conclusion

We have synthesised and characterised a series of lanthanide tetraalkyne DOTAM
complexes. Solution phase 1H NMR and solid state structures indicate that only SAP
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geometry is present in these compounds, which is useful for development of magnetic
resonance spectroscopy (MRS) and is critical for paramagnetic chemical exchange
saturation transfer (ParaCEST) MR imaging agents. The complexes Tm-3.1, Dy-3.1 and
Tb-3.1 show strong CEST signals due to the exchangeable amide protons at 25˚C, at 10
mM, pH 7. A response of 40% is observed for Eu-3.1 at 51ppm along with significant
CEST effect (~5%) due to metal-bound water was observed for Tb-3.1 and Dy-3.1 at –
640 and -765 ppm, respectively. Complexes producing such highly shifted signals are of
interest in the development of ParaCEST contrast agents that are free of interference from
background magnetization transfer effects.
We have also the used “click” chemistry to functionalize the central ligand in good yields
en route to the development of targeted contrast agents. Relaxivity measurements were
used to characterize the gadolinium-containing parent and derivative agents. All of these
agents possess smaller r1 values than the carboxylate ligand DOTA, which is expected on
the basis of slower water exchange in the DOTAM complexes. CEST experiments were
performed on Tm-(3.2,3.3), Tb-(3.2,3.3), Dy-(3.2,3.3), and Eu-(3.2,3.3). Tm-3.3 shows
a significant amide CEST response for what can be considered a targeted contrast agent
for glucose receptors as well as Eu-2 and Eu-3 which show promising results for bound
water. Dy and Tb complexes did not have any observable CEST response for both amide
and water.
Previous studies have shown that glucose conjugates can cross the blood-brain barrier,26
and target cancerous tissues due to their high demand for glucose.15,

16

Bearing these

59

results in mind, we have pursued a flexible “click” chemistry synthesis of multivalent
carbohydrate decorated MR contrast agents.

Table 3.6. Crystallography data for Nd-3.1, Yb-3.1, Tb-3.1 and Dy-3.1
Compound reference Tb-3.1
C28H42N8O5Tb
Chemical formula
(C3H15O5Cl3)
Formula Mass
967.12
Crystal system
Triclinic
a/Å
10.8916(5)
b/Å
14.3620(6)
c/Å
15.4604(10)
α/°
113.338(2)
β/°
103.205(3)
γ/°
99.220(2)
Unit cell volume/Å3 2075.04(19)
Temperature/K
150(2)
Space group
P1̄
No. of formula units
per unit cell, Z
2
No. of reflections
measured
246235
No. of independent
reflections
10723
Rint
0.0518
Final R1 values (I >
2σ(I))
0.0224
Final wR(F2) values
(I > 2σ(I))
0.0574
Final R1 values (all
data)
0.0263
Final wR(F2) values
(all data)
0.0598

Dy-3.1
C28H42N8O5Dy
(C3H16O5Cl3)
971.70
Triclinic
10.8844(4)
14.3626(6)
15.4658(10)
113.395(3)
103.121(3)
99.252(2)
2074.15(18)
150(2)
P1̄

Nd-3.1
C28H42N8O5Nd
(C3H16O5Cl3)
953.44
Triclinic
11.1524(6)
13.9136(7)
15.2106(12)
110.878(3)
103.133(3)
100.034(2)
2061.4(2)
150(2)
P1̄

Yb-3.1
C28H42N8O5Yb
(C3H12O5Cl3)
977.20
Triclinic
10.8858(5)
14.3185(6)
15.4483(7)
113.484(2)
102.767(2)
99.404(2)
2067.00(16)
150(2)
P1̄

2

2

2

286221

220951

278130

12145
0.0682

9849
0.0831

10268
0.1154

0.0237

0.0269

0.0303

0.0593

0.0615

0.0631

0.0289

0.0347

0.0431

0.0620

0.0647

0.0683
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3.4 Supplemental information
S3.1. NMR Spectra of Yb-3.1

S3.2. NMR Spectra of Ce-3.1
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S3.3. NMR Spectra of Eu-3.1

S3.4. NMR Spectra of Tm-3.1
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S3.5. NMR Spectra of Tb-3.1

S3.6. NMR Spectra of Er-3.1
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S3.7. NMR Spectra of Gd-3.1

S3.8. NMR Spectra of Ho-3.1
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S3.9. NMR Spectra of Dy-3.1

S3.10. NMR Spectra of Sm-3.1
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S3.11. NMR Spectra of Nd-3.1

S3.12. NMR Spectra of Pr-3.1
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S3.13. NMRD Profile of Gd-3.1
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S3.14. NMRD Profile of Gd-3.2
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S3.15. NMRD Profile of Gd-3.3
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S3.16.CEST Spectra of Dy-3.1
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S3.17.CEST Spectra of Dy-3.2
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S3.18.CEST Spectra of Dy-3.3
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S3.19.CEST Spectra of Eu-3.1
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S3.20.CEST Spectra of Eu-3.2
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S3.21.CEST Spectra of Eu-3.3
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S3.22.CEST Spectra of Tb-3.1
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S3.23.CEST Spectra of Tb-3.2
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S3.24.CEST Spectra of Tb-3.3
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S3.25.CEST Spectra of Tm-3.1
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S3.26.CEST Spectra of Tm-3.2
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S3.27.CEST Spectra of Tm-3.3
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S3.28. HPLC Trace of 3.2
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S3.29. HPLC Trace of 3.3
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S3.30. Relaxivity comparison of Gd series at 20 MHz

S3.31. Relaxivity comparison of Gd series at 400 MHz
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S3.32. CEST comparison of Eu series (Water)

S3.32. CEST comparison of Tm series (Amide)
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Chapter 4: Development of TSAP Based ParaCEST Agents

“DOTAM-based ParaCEST Agent Favoring TSAP Geometry for Enhanced
Amide Proton Chemical Shift Dispersion and Temperature Sensitivity”. Todd K.
Stevens*, Mark Milne*, Adam A. H. Elmehriki, Mojmir Suchý, Robert Bartha,
Robert H. E. Hudson. Contrast Media Mol. Imaging. 2012, 3, 289–292.

4.1 Introduction

The use of paramagnetic chemical exchange saturation transfer (paraCEST) contrast
agents have shown promise in sensing environmental conditions within in vivo systems.1,
2

However, a challenge in using paraCEST methods in–vivo, is the loss in sensitivity due

to magnetization transfer (MT) from endogenous macromolecules following the
application of radiofrequency (rf) saturation pulse.3 The MT effect is a competing
mechanism that saturates bulk water spins lowering the contrast efficiency of paraCEST
agents within the MT frequency range.

Consequently, a paraCEST agent with an

exchangeable proton pool exhibiting a chemical shift beyond the MT bandwidth would
be highly desirable.

Contrast agents incorporating the cyclen macrocycle such as DOTA, DOTAM, and their
derivatives exist in either a square antiprismatic (SAP) geometry or a twisted SAP
(TSAP) geometry, which describes the relative orientation between the planes of nitrogen
and oxygen atoms in the chelate.4, 5 To date, most paraCEST agents have been optimized
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for molecular water exchange, in which the slower exchange rates yielded by SAP
geometry chelates are often advantageous for contrast generation.4-7

For paraCEST

chelates such as DOTAM, the amide group provides a second pool of magnetically
distinct protons that are in exchange with the bulk water pool.8-16 Unlike bound water
based paraCEST, amide paraCEST signals can potentially be detected in both SAP and
TSAP chelate isomers. As the amide exchange rate should be insensitive to the
macrocycle geometry, the principal SAP/TSAP effect on the amide CEST signal is a
change in the lanthanide–induced frequency shift arising from a variation of the amide
proton to lanthanide distance or orientation or both.17 The presence of two distinct Tm3+
DOTAM t–butyl isomers in solution is expected to give rise to two unique chemically
shifted amide proton frequencies. If an isomer produces a signal at a chemical shift that
is greater than the frequency associated with endogenous MT, an increase in in vivo
detection sensitivity could be realized. Given the paucity of data on the paraCEST
properties of DOTAM-based agents possessing predominently TSAP geometry, we have
prepared and evaluated such an agent in order to investigate the effect of the geometry on
the chemical shift dispersion of the exchangeable amide proton pool.

4.2 Results and Discussion

The paraCEST agent biased toward TSAP geometry was synthesized by incorporating
the bulky t–butyl amide group in combination with the later lanthanide metal thulium
(Tm3+).18 Full synthetic details of Tm3+ DOTAM t-butyl are listed in supplemental
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information . This compound has been previously synthesized in efforts to modulate the
SAP/TSAP ratios for the purpose of optimizing exchange rates for bound–water
paraCEST; however, amide proton paraCEST has not been reported.19,

20

NMR signal

integration of the highly shifted cyclen proton peaks of Tm3+ DOTAM t–butyl
determined the population to be 66% TSAP isomer at 293 K, which is in agreement with
previous work.20 The proportion of TSAP isomer increased to 82% at 310 K, the
temperature used for the NMR experimentation described herein.

As shown previously, when two similar but distinct chelators are present (i.e.
stereoisomers), two unique signals can be observed, as is the case with the present
agent.21 To investigate the effect of the presence of two isomers, a z spectrum was
measured which showed two signals; one signal which was anomolously highly shifted (102 ppm). Thus, it was of interest to us to investigate the effect of increased chemical
shift on CEST contrast in the presence of an MT background. The CEST contrast for
Tm3+ DOTAM t–butyl was acquired and compared to that of a previously reported
dipeptide agent, Tm3+ DOTAM Gly–Lys–OH, which exists in a SAP geometry and
generates a CEST signal at –47 ppm relative to bulk water.22 In addition to characterizing
the CEST frequency response of the Tm3+ DOTAM t–butyl chelate, the temperature
sensitivity of these signals was evaluated over a biologically relevant range.

Aqueous solutions (10 mM) of Tm3+ DOTAM t–butyl (4.1) and Tm3+ DOTAM Gly–
Lys–OH (4.2) (Figure 4.1) were produced in 10% phosphate buffered saline to control
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pH and 90% D2O to mitigate radiation damping effects as well as increase CEST signal
amplitudes via slower T1 relaxation, thus optimizing the evaluation of frequency
information in the CEST spectra. To mimic the MT background signal found in in vivo z
spectra, both agents were also evaluated in the presence of heat–prepared 6% (w/w) agar
gel using the same solvent as above. All samples were tested at 310 K.

Figure 4.1. Chemical structure of Tm3+ DOTAM t–butyl (4.1) and Tm3+ DOTAM Gly–
Lys-OH (4.2).

First, z spectra were acquired for both the Tm3+ DOTAM t–butyl and Tm3+ DOTAM
Gly–Lys-OH agents without (Figure 4.2a) and with (Figure 4.2b) agar gel using 2 s
continous wave (cw) saturation. The saturation frequency offset was varied between –
150 ppm to 150 ppm (relative to the bulk water signal) in a random order to allow for
retrospective correction of small baseline drifts without affecting measured CEST or MT
effects. The z spectra were normalized against true baseline data that were acquired with
saturation offsets of ±1000 ppm to eliminate any possible inference from CEST, MT and
direct saturation effects. A 10 s repetition time delay was used to prevent T 1 weighting
between successive acquisitions (T1 time constants were determined to be between 1.1 s
and 1.2 s using a saturation recovery sequence). The CEST contrast represented by the
asymmetry in the longitudinal magnetization Mz about the bulk water frequency
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(calculated as Mz,off – Mz,on where “off–resonance” describes positive saturation
frequency offsets and “on–resonance” describes negative offsets) was also calculated for
each z spectra (Figure 4.2, insets). To investigate the amide proton exchange dynamics
underlying observed differences in CEST contrast due to the presence of an MT
background, the z spectra for the two Tm3+ DOTAM t–butyl samples were modeled with
McConnell–Bloch equations.23 From these 3–pool (no agar) and 4–pool (agar) models,3
effective exchange rates for the more highly shifted amide proton pool (–102 ppm) were
determined and compared.

Secondly, the temperature sensitivity of the Tm3+ DOTAM t–butyl amide CEST signals
was investigated. Windowed z spectra were acquired at 0.2 ppm intervals around the
amide proton frequency of the two isomers (–102 ppm and –68 ppm) to determine the
chemical shift changes of these CEST signals over the physiologically relevant
temperature range of 308 K to 315 K (Figure 4.3a). The precise chemical shifts were
determined with bi–Gaussian fitting of the windowed peaks, and the temperature
responses of the peaks were fit to determine a linear rate of frequency change with
temperature (Figure 4.3b).

In the absence of macromolecule MT signal loss, the difference in z spectrum water
linewidths for the Tm3+ DOTAM t–butyl and Tm3+ DOTAM Gly–Lys–OH samples was
evident (Figure 4.2a). This difference is explained by the higher molecular water
exchange rate associated with the TSAP geometry of the Tm3+ DOTAM t–butyl agent
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(approximately 67% TSAP), which minimizes the intermediate exchange regime line
broadening (due to interactions with Tm3+) seen in the slower DOTAM Gly–Lys–OH
agent. By matching the two Tm3+ DOTAM t–butyl CEST signal amplitudes to the isomer
ratio determined by integration of the cyclen proton signals,20 the more disperse signal at
–102 ppm most likely arises from the TSAP isomer, however no direct evidence has been
acquired to link the exchangeable proton to TSAP geometry. In the Tm3+ DOTAM t–
butyl samples with and without agar (Figure 4.2, blue), the ability to identify both the
assumed TSAP signal at –102 ppm and the assumed SAP signal at –68 ppm demonstrates
that the interconversion between these two isomers is slow relative to the NMR
timescale; specifically, the interconversion rate must be much smaller than the 20 kHz
chemical shift difference between these signals.
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Figure 4.2. Z spectra for 10 mM aqueous solutions of Tm3+ DOTAM t–butyl (4.1, blue
line) and Tm3+ Gly–Lys–OH (4.2, red line), both without (a) and with (b) 6% w/w agar
gel (2s, 20 µT saturation, 310 K, acquired at 14 T). Shown are amide CEST signals at –
102 ppm and –68 ppm assigned to the TSAP and SAP conformations of agent 4.2,
respectively. The signal at –47 ppm is due to agent 4.1 (in a SAP conformation).
Asymmetry differences (i.e. CEST contrast) for these amide proton signals are shown
inset. The arrow in (b) highlights a decrease in contrast from Tm3+ DOTAM–Gly–Lys–
OH (4.2) relative to that of the Tm3+ DOTAM t–butyl (4.1) in the presence of the MT
background.

93

For the samples without agar (Figure 4.2a), the CEST contrast produced at –102 ppm by
the Tm3+ DOTAM t–butyl agent was similar to that produced at –47 ppm by the Tm3+
DOTAM Gly–Lys–OH agent (17.5% and 15.6%, respectively), while 5.8% contrast was
observed at the –68 ppm offset for Tm3+ DOTAM t–butyl. In the presence of MT effects
from agar (Figure 4.2b, blue), the CEST contrast associated with the Tm3+ DOTAM t–
butyl sample was approximately half: 8.3% at –102 ppm and 3.2% at –68 ppm.
McConnell–Bloch modeling of the z spectra (not shown) suggested that this loss in
contrast, despite a lack of overlap with the MT background, was likely due to decreases
in the effective exchange rates between the amide proton and bulk water proton pools.
Specifically, the effective exchange rate for the highly shifted amide proton pool, which
represents information about both the proton exchange rate at the amide site as well as
the bulk diffusion rate of protons in the sample, was determined to be 0.9 kHz without
agar, and 0.5 kHz with agar present. Possible mechanisms for this rate reduction may
have been hydrogen bonding interaction of the paraCEST amide protons with the agar
matrix or a reduction in water diffusion due to long–range restrictions imposed by the
agar matrix over the 2 s saturation time. Reduced diffusion would result in slower
refreshment of unsaturated protons in the water hydration layer accessible to the amide
site, and thus lower CEST contrast. For the Tm3+ DOTAM Gly–Lys–OH agent, the
CEST contrast was reduced by a factor of four down to 4.2% when agar was introduced
(Figure 4.2b, red). Although the exchange dynamics are likely slowed by the agar matrix
similar to those of the Tm3+ DOTAM t–butyl agent, the more pertinent source of contrast
loss for this agent is likely the competing MT effect, which produces enough saturation at
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–47 ppm to limit the efficiency of the CEST mechanism (i.e. the agent is less likely to be
acting on previously unsaturated protons).

Evaluation of the temperature dependence of the amide proton chemical shifts showed a
distinct difference between the assumed SAP and TSAP geometries. While both SAP
and TSAP amide proton shifts varied linearly with temperature (Figure 4.3b), those
associated with the highly shifted protons (-100 ppm, 0.57 ppm/K) were over three times
more sensitive than the inside amides shift (-65 ppm, 0.16 ppm/K). Since these measures
are based on frequency, they reflect the ability to monitor temperature in an agent
concentration–independent manner. Moreover, the amplitude of the observed CEST
contrast also increased with increasing temperature, from 16.3% to 24.9% for the TSAP
amide proton signal and from 5.0% to 8.9% for the SAP signal over the range of 308 K to
315 K. These increases in contrast at elevated temperatures are likely due to faster amide
proton exchange24 combined with more rapid turnover of the water hydration layer.
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Figure 4.3. Plots showing the CEST chemical shift variation with temperature for the
amide pool of Tm3+ DOTAM t–butyl (4.1) in both SAP and TSAP conformations.
Experiments were performed at 14 T using a 10 mM aqueous solution (90% D2O) of the
agent and 2 s, 20 uT rf saturation. (a) Windowed z spectra showing the post–saturation
Mz CEST signals at –68 ppm and –102 ppm, with the direction of variation due to
increasing temperature shown in red. (b) Chemical shift values and best fits
demonstrating the linear response of the SAP and TSAP shifts with temperature.
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4.3 Conclusion

In conclusion, it has been shown that DOTAM–based paraCEST agents with a TSAP
geometry may produce increased chemical shift dispersion of the exchangeable amide
protons. The more highly shifted signals possess greater temperature sensitivity than less
shifted signals. To our knowledge, these results represent the largest frequency offset of a
paraCEST amide proton signal at physiological temperatures, which may facilitate
paraCEST detection in the presence of MT background signals such as those
characteristic of in-vivo systems.
A secondary paper to this research in which I was second author was published in Can. J.
Chem in 2012.18 In this paper we discuss the synthesis of not only the agent in this paper,
Tm3+ t-butyl, but a series of 7 chelators that incorportated alkyl groups other then t-butyl.
This series was then metallated with Dy3+, Tb3+ or Tm3+ giving a total of 21 new contrast
agents. After their synthesis was completed their amide ParaCEST properties were
studied. Further discussion of this paper will not be found in this thesis, but I believe that
the recognition of Adam Elmehriki to the synthesis of these agents is important.
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4.4 Supplemental information

Scheme S4.1: Synthesis of Tm3+ DOTAM t-butyl

S4.2 Synthesis of agents used.
Preparation of N-t-butyl chloroacetamide (4.5): Chloroacetyl chloride (4.3, 1.03 ml,
13 mmol) was added dropwise (within 1 minute) to a suspension of t-butylamine (4.4,
1.05 ml, 10 mmol) and Na2CO3 (2.12g, 20 mmol) in dry DMF (2 ml) cooled to 0 °C. The
cooling bath was removed and the mixture was stirred for 24 h at room temperature (rt).
Saturated solution of NaHCO3 (50 ml) was added to the mixture followed by the
extraction with EtOAc (2 × 40 ml). The combined organic extract was washed with brine
(2 × 40 ml), was dried and was concentrated to dryness. The residue was crystallized
from CH2Cl2/hexanes to give N-t-butyl chloroacetamide (4.5) as colorless crystals (658
mg, 44%). 1H NMR (CDCl3) δ 6.38 (s, D2O exch., 1H), 3.93 (s, 2H), 1.37 (s, 9H);

13

C

NMR (CDCl3) δ 164.8, 51.7, 42.9, 28.4. HRMS (EI) m/z; found 140.0608 [M]+ (calcd.
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149.0607 for C6H12ClNO); LRMS (EI) m/z (rel. abundance): 149 [M+] (50), 134 (100),
84 (48). Spectral data were in agreement with those previously reported.
Preparation of N-t-butyl iodoacetamide (4.6): Sodium iodide (1.262 g, 8.42 mmol) was
added to a solution of N-t-butyl chloroacetamide (4.5, 420 mg, 2.81 mmol) in acetone (18
ml). The mixture was stirred for 24 h at rt, was concentrated to ca. one third of its
original volume, was diluted with EtOAc (30 ml) and was washed with 10% Na2SO3
solution (20 ml). An aqueous phase was then extracted with EtOAc (20 ml); combined
organic extract was dried and was concentrated to dryness. The residue was crystallized
from CH2Cl2/hexanes to give N-t-butyl iodoacetamide (4.6) as pale yellow crystals (464
mg, 68%). 1H NMR (CDCl3) δ 5.92 (s, D2O exch., 1H), 3.62 (s, 2H), 1.35 (s, 9H);

13

C

NMR (CDCl3) δ 165.9, 51.9, 28.3, 1.2. HRMS (EI) m/z; found 240.9966 [M] + (calcd.
240.9964 for C6H12INO); LRMS (EI) m/z (rel. abundance): 240 [M+] (95), 226 (100),
186 (40), 84 (52). Spectral data were in agreement with those previously reported.1

Preparation of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(N-t-butyl)acetamide
(4.8): DIPEA (280 μl, 1.6 mmol) was added to a solution of cyclen (4.7, 69 mg, 0.4
mmol) in MeCN (4 ml). The mixture was stirred at 45 °C for 10 min followed by the
addition of N-t-butyl iodoacetamide (4.6, 386 mg, 1.6 mmol). The mixture was stirred for
24 h at 45 oC. It was the cooled to rt, was diluted with H2O (20 ml) and was extracted
with EtOAc (3 × 20 ml). The combined organic extract was dried and was concentrated
to dryness. The residue was crystallized from MeCN to give DOTAM t-butyl (4.8) as a
colorless solid (135 mg, 49%). 1H NMR (CDCl3) δ 6.57 (m, D2O exch., 4H), 3.10-1.90
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(broad m, 24H) 1.36 (s, 36H);

13

C NMR (CDCl3) δ 170.4, 58.4, 51.7, 28.9, 28.6.

NMR (CD3 D) δ 3.05 (m, 8H), 2.79 (m, 16H), 1.36 (s, 36H);

13

1

H

C NMR (CD3 D) δ

173.0, 60.6.4, 54.5, 52.1, 29.3. HRMS (ESI) m/z; found 625.5115 [M + H]+ (calcd.
625.5129 for C32H65N8O4). Spectral data in CD3OD were in agreement with those
previously reported.
Preparation

of

Tm3+-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(N-t-

butyl)acetamide chloride (4.1): TmCl3 • H2O (54 mg, 0.134 mmol) was dissolved in
H2

(500 μl), the resulting solution was added to a solution of D TAM t-butyl (4.8, 80

mg, 0.116 mmol) in dioxane (2 ml). The mixture was stirred at 70 °C for 24 h. The
mixture was concentrated to dryness, followed by FCC on 15 g Al2O3, eluted with
CH2Cl2/MeOH/NH4OH (60:39:1). The fractions containing the desired compound (I2
vapour visualization) were concentrated to dryness, the residue was dissolved in H2O; pH
was adjusted to 7 with (1 M HCl). The solution was transferred into a dialysis bag and
was dialysed (against H2O) for 120 h.

The concentration of the aqueous solution

afforded the Tm3+ DOTAM t-butyl (7) as a colorless solid (53.8 mg, 54%). HRMS (ESI)
m/z; found 791.4205 [M - 2H]+ (calcd. 791.4236 for C32H62N8O4Tm).
S4.3. CEST Discussion
Although 90% D2O sample solutions were used, the CEST results may be extrapolated to
100% H2O systems since the concentration ratio of protons to agent available for proton
binding, upon which CEST contrast is highly dependent, is unchanged in the present
system (i.e. the signal of approximately 11 M of bulk protons is being modulated by one–

100

tenth of the agent with the balance 90% being engaged with deuterium exchange at any
given moment).
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Chapter 5: Synthesis and Characterization of Aniline
Containing ParaCEST Agents

“MRI ParaCEST agents that improve amide based pH measurements by
eliminating inner sphere water T2 exchange” Mark Milne, Melissa Lewis, Nevin
McVicar, Mojmir Suchý, Robert Bartha, Robert H. E. Hudson. Submitted to RSC
Advances, 2013. Manuscript # RA-ART-07-2013-043537.

5.1 Introduction

Lanthanide based contrast agents (CAs) have been exploited for a number of years in
magnetic resonance imaging (MRI) with coordinated gadolinium (Gd3+) agents being
used primarily in clinical environments.1-5 Of these agents cyclen-based macrocyclic
agents have been predominantly utilized as chelators because of the high stability of the
resulting metal complexes under in vivo conditions.

It has been shown that cyclen-based agents can adopt two main geometries in solution.
The first geometry is a square antiprismatic (SAP) while the second is a twisted square
antiprismatic (TSAP).6, 7 In solution, these geometries can be identified by the chemical
shifts of the cyclen backbone with their interconversion measured by EXSY NMR
experiments. In solid state, the two geometries can be distinguished by the angle between
planes of N-Ln-N and O-Ln-O. When the angle between the aforementioned planes is
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~40°, the structure is assigned to the SAP form, while angles closer to 30° are assigned
the TSAP form.

Of these two forms, it has been shown that the TSAP geometry

possesses a faster exchange of bound water compared to the SAP form, which is thought
to occur because of the more open structure TSAP displays.8

A promising technique for the in vivo measurement of tissue environmental conditions is
the use of chemical exchange saturation transfer (CEST) or paraCEST, when a
paramagnetic species is used as a hyperfine shift agent.9-12 The CEST and paraCEST
techniques require exchangeable protons to transfer saturation to the bulk system,
creating an overall decrease in the bulk water magnetization.13-15 The exchangeable
proton sources are usually bound water as seen in Eu3+-containing paraCEST agents or
amides, amines or alcohols in either diamagnetic CEST agents or in lanthanide paraCEST
complexes.16-19 Because these agents use saturation transfer of exchangeable protons,
their exchange properties can be related to the environment around the agent.

For

example, temperature and pH both modulate the proton exchange rate, particularly when
using the highly shifted paraCEST agents that utilize Eu3+, Dy3+, Tb3+ or Tm3+ ions.20, 21
While there have been numerous agents that are capable of reporting pH and
temperature,12,

22-26

some of these agents either do not function at physiological

temperatures, or their optimal pH response is above 7, which is outside the physiological
range of interest. These drawbacks demonstrate the need to design agents that are
responsive to the physiological parameters of interest, most notably when the tissue is
slightly acidic (pH 6-7) and at temperatures between 35 °C - 45 °C. To address these
issues, we have synthesized a series of Dy3+ and Tm3+ DOTAM anilides that are para-
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substituted, which should allow for the modulation of the amide’s pKa based on the
electron donating/withdrawing nature of the substituent. (Figure 5.1)
Although paraCEST agents are generally inefficient at inducing T1 relaxation, such
agents are capable of producing significant signal loss during in vivo imaging,27, 28 due to
increased transverse relaxation mediated by water exchange (T2 exchange) from the inner
sphere to the bulk water. The use of ultra-short echo-time (UTE) pulse sequences can
reduce this effect, as observed with the SWIFT pulse sequence when used for paraCEST
imaging.29 However, such sequences are not standard on most clinical scanners limiting
their applicability. Therefore, we hypothesized that a paraCEST agent designed to reduce
T2 signal losses would therefore be of benefit. To this end, we have developed agents that
do not contain inner sphere water and therefore are inefficient modulators to the bulk
water T2 relaxation time constant. It must be noted that the amides that generate the
CEST effect will still induce T2 relaxation, but to a much less extent compared to bound
water.

Figure 5.1. Lanthanide-based CAs synthesized.
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Similar studies have been performed to monitor and adjust the water exchange rate on a
series of Eu3+-based ParaCEST agents.30 While those results demonstrate the ability to
modulate the bound water exchange rate based on the electron donating and withdrawing
properties of the substituents, the effect of para-substitution on amide proton exchange of
anilides was not studied. The use of Eu3+ as the lanthanide limits the ability to monitor
how the amide is affected by the substitutions because the amides will exhibit a small
shift compared to that induced by other lanthanides such as Dy3+, Tm3+ or Tb3+.

5.2 Results and Discussion
Synthesis of agents 5.3a-e , 5.4a-e
The electrophiles 5.1a-e were synthesised by adding chloroacetyl chloride to the
appropriate aniline in acetonitrile while cooled in an ice bath in the presence of potassium
carbonate (Scheme 5.1). The reactions were stirred overnight at room temperature, then
filtered and the crude products were recrystallized from methanol. The average yield of
these reactions was good (~75%).

Syntheses of the tetra-substituted cyclens were

performed by mixing cyclen with 4.5 eq of the appropriate electrophiles in acetonitrile in
the presence of potassium carbonate. It was necessary to heat the reaction at 55 °C - 80
°C over 1-3 days to ensure complete tetraalkylation. The progress of these reactions was
monitored by UPLC MS. When the reaction was deemed complete, the mixtures were
cooled and the product was allowed to precipitate along with the K2CO3. The mixture
was then filtered and the precipitate was washed with cold water to remove the K2CO3.
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At this point, attempts to recrystallize these compounds from methanol were unsuccessful
due to their solubility properties. As such, the crude products were used without further
purification. Crude yields ranged from of 94% to quantitative. The tetra-substituted
cyclen products were then metallated using either DyCl3 or TmCl3 in a 1:1 water:dioxane
mixture at 80 °C over 4 days. The metallated complexes were subjected to dialysis
against water across a membrane with a 500 Dalton molecular weight cutoff to remove
salts carried through from the previous step as well as unchleated lanthanide ion.

The

final products were isolated by lyophilization to give white powders, with exception of
the p-nitro compound being a yellow powder. Identification of the metallated products
was accomplished by high resolution mass spectrometry along with their UPLC trace
which showed that all of the samples to be homogeneous tetra-substituted product.
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Scheme 5.1. Conditions for the synthesis of lanthanide-based CAs. i) Acetonitrile,
K2CO3, Room temperature overnight. ii) Acetonitrile, K2CO3, 55 – 80 °C 2-3 days. iii)
1:1 H2O:Dioxane, DyCl3 or TmCl3, 60 – 80 °C, 4 days.
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CEST Evaluation
To study how the para-substitution affects the amide exchange rate of the Tm3+ and Dy3+
DOTAM anilides (5.3a-e, 5.4a-e), we began with a pH study of the series at 20 mM.
Quickly, we discovered many of the compounds were not sufficiently soluble to achieve
this concentration, except for the unsubstituted anilides (5.3a, 5.4a) and the para-OMe
anilides (5.3b, 5.4b). Unfortunately, the rest of the series (5.3c-e, 5.4c-e) was not soluble
enough to permit collection of reliable CEST spectra even at 5 mM. For the soluble
5.3a,b and 5.4a,b complexes, CEST experiments were performed using a 15 uT
saturation pulse for 5 seconds at steps of 1 ppm from -100 ppm to 100 pm in the pH
range of 6.5 to 9.0 for the unsubstituted anilides and the range of 5.1 to 8.0 for the paraOMe anilides. These ranges were chosen because of the observation that the maximum
CEST effect was close to 8.0 for the unsubstituted anilides while the maximum CEST
effect was between 7.0 - 7.5 for the para-OMe anilides. Of interest, we observed that the
Tm3+ para-OMe (5.3b) compound displayed two CEST signals due to slow
conformational equilibrium between the SAP and the TSAP geometries while the Dy3+
agent (5.4b) produced only one measurable signal. We have previously observed this
feature during the study of a series of alkyl amides and designated the rarely seen higher
shifted amide signal to a TSAP geometry while the signal less shifted is closer to the
normally observed SAP geometry amide.10, 31 This feature appears to be limited to Tm3+
agents and could be possibly due to the smaller lanthanide size compared to the Dy3+,
thus exacerbating steric interactions. The CEST spectra as a function of pH for 5.3a and
5.3b are shown in figure 5.2, with the CEST response for each of the 4 agents measured
at pH 7.0 reported in table 5.1.
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Figure 5.2. Top) CEST intensity of 5.3a over the pH range of 6.5-9.0. Bottom) CEST
intensity of 5.3b over the pH range of 5.1-7.0. CEST spectra were acquired at 37 °C, 15
uT, 5 s.

Table 5.1. CEST % measured at pH 7, 37 °C, 20 mM with a saturation
pulse of 15 uT for 5 s.
Agent
ppm (δ)
CEST %
5.3a

-41

20%

5.3b

-43

17%

-83

15%

5.4a

70

6%

5.4b

74

3%
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Figure 5.3 shows how the CEST effect of agents 5.3a and 5.3b changes over the pH
ranges measured. The signal for the Tm3+-para-OMe TSAP amide (-83 ppm) has a
maximum signal at a slightly more acidic pH (7.0) compared to the SAP (-43 ppm) amide
(pH 7.5). This effect has been observed previously for DOTAM agents where the signal
possessing the greater chemical shift displays a maximum signal at lower pH compared
to the signal with a smaller chemical shift.32
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Figure 5.3. Maximum CEST response over a pH range. Top) 5.3a shows a pH maximum
at 8.0. Bottom) 5.3b shows a pH maximum at 7.5 for the signal at -43 ppm and at 7.0 for
the signal at -83 ppm.
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An effective MRI CA for pH measurement must show a monotonic response to pH and
must provide a concentration independent measurement. Both conditions are violated by
these agents, although the first issue can be minimized by rationalizing that it would be
rare to observe a pH above 8 in vivo. One method to overcome the concentration
dependence is illustrated in Figure 4. Using a line width analysis, Tm3+ p-H (5.3a) can be
used as a pH reporter with a monotonic response to pH over the range of 6.5 to 8.5 by
following the procedure described in McVicar et. al.12

Figure 5.4. Line width analysis vs. pH of a 20 mM solution of Tm3+ p-H (5.3a) at 37°C,
15 µT, 5 s.

Another approach to overcome concentration dependence is to implemented a ratiometric
approach as previously described, where two intramolecular signals are evaluated
simultaneously.22, 33 In particular, when two CEST responses arise from a single agent a
ratio of the CEST effect eliminates the concentration dependence and enables the agent to
be used as a physiological reporter. Since Tm3+-para-OMe possesses two intramolecular
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amide signals that behave slightly different based on pH, we examined the possibility of
using it as a ratiometric pH reporter. However, small pH responses and limited solubility
of the Tm3+-para-OMe agent frustrated attempts to demonstrate that this agent could be
used as a concentration independent pH reporter (Data not shown). We are currently
developing synthetic avenues to make this agent more pH responsive, as well as, increase
its solubility to extend its functionality.

X-Ray Structures
Crystals suitable for X-ray diffraction were grown from slow evaporation of a
concentrated solution of Tm3+-para-OMe (5.3b) in water.

Figure 5.5 illustrates a

molecular representation of 5.3b at 50% probability for the ellipsoids. It has been shown
that macrocyclic CAs based on cyclen can exhibit a 9 coordination geometry around the
lanthanide, where 8 of the coordination sites are filled with 4 nitrogens of the cyclen and
4 oxygens from the carbonyls pendant groups. The ninth coordination site is typically
occupied by a water molecule that can be exchanged with the bulk water system and can
be used to enhance relaxation or transfer saturation to the bulk system.
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α

Figure 5.5. Molecular representation of the solid state structure of Tm3+-para-OMe
(5.3b) determined by single crystal X-ray studies. Hydrogens have been omitted for
clarity. Left) Side on view of 3b showing eightfold coordination of the Tm3+ by the
nitrogens of cyclen and the oxygens of the amide pendant groups. Right) Top down view
of 5.3b. The aniline rings are omitted for clarity. α indicates the angle created between
the planes of N-Ln-N and O-Ln-O and is listed in Table 10 along with selected angles
and bond lengths.

X-ray crystallography determined an 8 coordination system around the Tm 3+ ion, with the
8 sites filled by either nitrogen atoms or oxygen atoms. The ninth potential coordination
site was unoccupied - no bound water was found to directly coordinate the metal centre.
This distinction has been observed before for lanthanide based CAs and has been denoted
by ascribing a prime (') to the end of the geometry abbreviation.7,

34-36

The α angle

created between the planes of N-Ln-N and O-Ln-O is used in determining which
geometry is present. Angles that near 40° are in a SAP geometry while angles that are
closer to 30° are in the TSAP geometry.37 In the case of the Tm3+ para-OMe, the
geometry is a TSAP' system with an α angle of 27° and lacking inner sphere water, while
the other geometry that is present is thought to be SAP' due to the bulkiness of the
ligands. Selected angles and distances are listed in Table 5.2 and more detailed
crystallographic parameters in Table 5.3.
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Table 5.2. Summary of torsion angle α (°) and selected bond lengths (Å)
for Tm3+ para-OMe (5.3b).
α angle
N1-C-C-O1
N2-C-C-O2
N3-C-C-O3
N4-C-C-O4

26.95
12.35
15.14
14.65
2.95

N1-Ln
N2-Ln
N3-Ln
N4-Ln
O1-Ln
O2-Ln
O3-Ln
O4-Ln

2.508
2.492
2.469
2.500
2.295
2.245
2.314
2.266

Table 5.3. Crystallographic Information for 5.3b
Formula
Formula Weight (g/mol)
Crystal Dimensions (mm )
Crystal Colour and Habit
Crystal System
Space Group
Temperature, K
a, Å
b, Å
c, Å
a,°
b,°
g,°
V, Å3
Number of reflections to determine final unit cell
Min and Max 2q for cell determination,
°Z
F(000)
r (g/cm)
l, Å, (MoKa)
m, (cm-1)

C44H67Cl3N8O13Tm
1191.34
0.27 × 0.18 × 0.08
colourless prism
triclinic
P -1
110
10.948(3)
14.438(3)
17.436(5)
77.345(10)
78.428(9)
85.152(10)
2632.1(12)
9059
4.88, 64.1
2
1222
1.503
0.71073
1.904
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Relaxation Evaluation
With the ninth site of Tm3+ para-OMe (5.3b) vacant of inner sphere water, relaxation
theory predicts that there should be sizable differences in the ability of this agent to
induce bulk water relaxation compared to similar agents that contain bound water.2,

38

While Tm3+ lanthanide agents are not thought to be efficient T1 relaxation agents they
have recently been shown to produce sizable T2 relaxation effects (Table 5.4). Soesbe et
al.28 compared several Eu3+ based agents that contained inner sphere water with one that
did not, and showed a darkening during in vivo paraCEST imaging of kidneys for those
agents that had intermediate inner sphere water exchange rates. The darkening was
linked to T2 shortening. Another Eu3+ agent that lacked an inner sphere water (Eu3+
TETA) showed very little T2 shortening and limited darkening. This shortening of the T2
time constant lead to a reduction in the image signal intensity and reduced CEST
contrast. Because Eu3+ based agents typically utilize the exchange of bound water from
the inner sphere to generate the saturation used in paraCEST imaging such agents may
also produce T2 related signal loss when images are acquired with non-zero echo-time.

Development of agents that do not contain inner sphere water, such as Tm3+ para-OMe
(5.3b) should have an advantage in -NH based paraCEST imaging as the major T2
shortening mechanism from water exchange has been removed. It should be noted that
the exchange of -NH protons of the anilides still contributes to the T2 relaxation of bulk
water, but to a lesser extent compared to highly shifted bound water.28 Figure 6 shows
the relaxation rate (R2) as a function of concentration for Tm3+ based agents that are
thought to either have bound water (Tm3+ DOTAM-Gly, Tm3+ DOTAM-Gly-Lys) and
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those that are thought to have no bound water (Tm3+ para-H (5.3a), Tm3+ para-OMe
(5.3b)). The associated longitudinal and transverse relaxivity (r1, r2) is provided in Table
5.4.

Figure 5.6. r2 evaluation of agents Tm3+ para-H (5.3a), Tm3+ para-OMe (3b), and Tm3+
DOTAM-Gly and Tm3+ DOTAM-Gly-Lys. The slope of the linear fit is used as the r2
value and reported in Table 5.4.

Table 5.4. r1 and r2 values of four Tm3+ at 37 °C, pH 7, 9.4 T.
Agent

q

r1 (s-1 mM-1)

r2 (s-1 mM-1)

Tm3+ para-H (5.3a)

0

0.06

0.67

Tm3+ para-OMe (5.3b)

0

0.05

0.36

Tm3+ DOTAM-Gly39

1

0.06

2.07

Tm3+ DOTAM-Gly-Lys40

1

0.09

5.75

The two anilide agents (5.3a, 5.3b) produced a significantly lower relaxation rate (Figure
5.6) because they do not possess an inner sphere water. None of the agents tested
produced strong T1 relaxation of the bulk water, which is not surprising as Tm3+ is not
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known to act as a T1 relaxation enhancer.27 The benefit of having CEST agents with
minimal effect on T2 relaxation is demonstrated in Figure 5.7. Two phantoms are shown,
one containing Tm3+ DOTAM-Gly-Lys as an example of a short T2 agent (large r2) and
the second containing Tm3+ para-OMe (5.3b) as an example of a long T2 agent (small r2).
T1 and T2 weighted images were acquired and demonstrate that Tm3+ DOTAM Gly-Lys
(Figure 5.7c) produces signal loss due to the T2 exchange effect, while Tm3+ para-OMe
(Figure 5.7d) does not have a large T2 exchange effect. The two phantoms were imaged
at a concentration of 20 mM and compared to aqueous solutions containing no agents
(outer circles in Figure 5.7). Both the signal to noise ratio (SNR) and CEST effect are
important properties that can be used to characterize CEST images. In medical imaging
practice however it is important to calculate the contrast to noise ratio (CNR) of CEST
images to quantify the likelihood of distinguishing between diseased and surrounding
normal tissue.41 In Table 5.5, several CEST image properties including the SNR, CEST
effect and CNR are provided for Tm3+-para-OMe and Tm3+ DOTAM-Gly-Lys. The
SNR is calculated using the signal intensity measured from the agent (inner circle) along
with the water (outer cirle) after applying a saturation pulse CEST while the CNR takes
into account the overall CEST response of each agent compared the SNR measured.
While Tm3+ DOTAM-Gly-Lys produces the largest CEST effect, the agent with the
longest T2, Tm3+-para-OMe, provides a significantly greater CNR. To visualize the
significance of SNR and CNR, Figure 5.7 provides a direct comparison of T1- and T2weighted images of 20 mM Tm3+-para-OMe and Tm3+ DOTAM-Gly-Lys phantoms
surrounded by an outer cylinder of distilled water. A 3.5% decrease in SNR was
calculated for the long T2 agent (Tm3+-para-OMe) while a 85% decrease was measured
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for the short T2 agent (Tm3+ DOTAM-Gly-Lys). It is apparent that even with a large
CEST effect, the overall detectability of Tm3+ Gly-Lys is substantially lower than Tm3+para-OMe due to the short bulk water T2 induced by Tm3+ DOTAM-Gly-Lys.

a)

b)

c)

d)

Figure 5.7. T1 and T2 weighted images collected at 37 °C and pH 7.0. Inner circle
contains 20 mM CAs. Outer circle contains water with no agents. T1 weighted images of
a) Tm3+ DOTAM Gly-Lys b) Tm3+ para-OMe. T2 weighted images of c) Tm3+ DOTAM
Gly-Lys d) Tm3+ para-OMe (5.3b).

Table 5.5. In vitro MR image contrast parameters for Tm3+ para-OMe and
Tm3+ DOTAM-Gly-Lys.
CEST (%)
CNR*
Bulk Water
Tm3+ para-OMe (-43 ppm)
Tm3+ para-OMe (-83 ppm)
Tm3+ DOTAM-Gly-Lys (-46 ppm)

-16.9
12.2
43.3

*SNR and CNR were calculated as defined in ref. 41. 41

-59.0
42.6
23.9
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Experimental
CEST fast spin-echo (FSE) images were acquired on a 9.4T MRI scanner (Agilent, Palo
Alto, CA) with the following parameters, FOV (field of view): 25.6 x 25.6 mm2, matrix:
64 x 64, TR: 5000 ms, TE: 10 ms, ETL = 32, 1 average, 2 prescans, 1 slice 3 mm thick.
CEST spectra (Tm3+ and Dy3+) were acquired using a 15 µT, 5s continuous wave
presaturation pulse at offset frequencies ranging from -100 to 100 ppm in steps of 1 ppm.
T1 weighted images were acquired using a gradient echo pulse sequence. TR = 200 ms,
TE = 2.62 ms, Flip angle = 20°, 10 averages, matrix = 128x128, FOV = 19.2 x 19.2 mm2,
1 slick 4 mm thick. All samples were studied at 20 mM concentration, 37 °C. All
solvents were HPLC grade and used as such, except for dioxane (dried by passing
through columns of activated Al2O3) and water (18.2 MΩcm-1 deionized). Solvents were
removed under reduced pressure in a rotary evaporator. NMR spectra were recorded on a
400 MHz spectrometer; for 1H (400 MHz), chemical shift values (δ) are reported relative
to TMS and were referenced to the residual proton in the deuterated solvents as follows:
CDCl3 (7.26 ppm); DMSO-d6 (2.49 ppm); D2O (4.75 ppm). Mass spectra (MS) were
obtained using electrospray ionization (ESI). T1 relaxation time constant measurements
were made for 4 different concentrations (1, 2, 4, 8 mM) of CA using an inversion
recovery sequence (10 inversion times in the range of 10 ms – 10 s) with a 20 second
repetition time to ensure full recovery, pH 7 and 37 °C. T2 rrelaxation time constant
measurements were made for 4 different concentrations (1, 2, 4, 8 mM) of CA using a
CPMG pulse sequence (10 train echo times in the range of 10 ms – 10 s) with a 20
second repetition time to ensure full recovery, pH 7 and 37 °C. Tm3+ DOTAM-Gly was
prepared previously.39 Tm3+ DOTAM-Gly-Lys was prepared previously.40
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General Procedure for Electrophiles 5.1a-e
Chloroacetyl chloride (15.7 mmol) was added slowly on ice to a stirring solution of
aniline (a-e) (7.84 mmol) and K2CO3 (15.7 mmol) in acetonitrile (50 mL). The solution
was allowed to stir overnight at room temperature followed by filtration. The filtrate was
concentrated and the product was crystallized from methanol.
5.1a. 2-chloro-N-phenylacetamide. White solid (1.06 g, 6.2 mmol) yield 80%. 1H NMR
(400 MHz, DMSO-d6): δ 10.36 (1H, s); 7.60 (2H, d, J = 7.4 Hz); 7.33 (2H, t, J =7.4 Hz);
7.08 (1H, t, J = 7.4 Hz); 4.26 (2H, s).

13

C NMR (100 MHz, DMSO-d6): δ 165.0, 138.9,

129.2, 124.2, 119.8, 44.0. ESI-TOF. m/z calcd for C8H9ClNO (M+H)+, 170.0373, found
170.0366.

5.1b. 2-chloro-N-(4-methoxyphenyl)acetamide. Silver solid (1.29 g, 6.5 mmol), yield
82%. 1H NMR (400 MHz, DMSO-d6): δ 10.17 (1H, s); 7.51 (2H, d, J = 8.6 Hz); 6.90
(2H, d, J = 8.6 Hz); 4.22 (2H, s); 3.72 (3H, s). 13C NMR (100 MHz, DMSO-d6): δ 164.5,
156.0, 132.0, 121.4, 114.3, 55.6. 43.9. ESI-TOF. m/z calcd for C9H11ClNO2 (M+H)+,
200.0478, found 200.0477.

5.1c. 2-chloro-N-(p-tolyl)acetamide. White solid (1.08 g, 5.9 mmol), yield 75%. 1H
NMR (400 MHz, DMSO-d6): δ 10.21 (1H, s); 7.50 (2H, d, J = 7.4 Hz); 7.13 (2H, d, J =
7.4 Hz); 4.24 (2H, s); 2.26 (3H, s).

13

C NMR (100 MHz, DMSO-d6): δ 164.8, 136.4,

133.2, 129.6, 119.8, 44.0, 20.8. ESI-TOF. m/z calcd for C9H11ClNO (M+H)+, 184.0529,
found 184.0524.

5.1d. 2-chloro-N-(4-nitrophenyl)acetamide. Yellow solid (1.80 g, 7.9 mmol), yield
79%. 1H NMR (400 MHz, DMSO-d6): δ 10.97 (1H, s); 8.22 (2H, d, J = 9.0 Hz); 7.84
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(2H, d, J = 9.0 Hz); 4.35 (2H, s). 13C NMR (100 MHz, DMSO-d6): δ 166.0, 145.0, 143.0,
125.4, 119.5, 44.0. ESI-TOF. m/z calcd for C8H8ClN2O3 (M+H)+, 215.0223, found
215.0220.

5.1e. 2-chloro-N-(4-chlorophenyl)acetamide. White solid (1.08 g, 5.3 mmol), yield
68%. 1H NMR (400 MHz, DMSO-d6): δ 10.43 (1H, s); 7.62 (2H, d, J = 8.6 Hz); 7.38
(2H, d, J = 8.6 Hz); 4.26 (2H, s). 13C NMR (100 MHz, DMSO-d6): δ 165.2, 137.8, 129.2,
127.9, 121.3, 43.9.

ESI-TOF. m/z calcd for C8H8Cl2NO (M+H)+, 203.9983, found

203.9983.

General Procedures for Tetra Substituted Cyclen 5.2a-e
Electrophiles 1a-e (2.25 mmol) in 3 mL acetonitrile were added to a stirring solution of
cyclen (0.5 mmol) and K2CO3 (2.25 mmol) in acetonitrile (12 mL). The reaction was
then stirred for 1-3 days at 55 °C - 80 °C and monitored by UPLC MS. Upon completion
the reaction was filtered and the precipitate washed with water, then collected and used
without further purification.

5.2a.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-

phenylacetamide). The title compound was obtained as a white powder (0.348 g) yield
quantitative (q). 1H NMR (400 MHz, DMSO-d6): δ 10.32 (4H, broad s); 7.61 (8H, d, J =
7.8 Hz); 7.22 (8H, t, J =7.8 Hz); 7.01 (4H, t, J = 7.8 Hz); 3.38 (16H, s); 2.81 (8H, broad
s). 13C NMR (100 MHz, DMSO-d6): δ 169.3, 138.5, 128.3, 123.0, 119.3, 58.1, 51.9. ESITOF. m/z calcd for C40H49N8O4 (M+H)+, 705.3877, found 705.399.
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5.2b.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-

methoxyphenyl)acetamide). The title compound was obtained as a white powder (0.389
g) yield 94%. 1H NMR (400 MHz, DMSO-d6): δ 10.04 (4H, broad s); 7.51 (8H, s); 6.80
(8H, s); 3.68 (16H, s,); 3.25 (12H, s); 2.84 (8H, broad s).

13

C NMR (100 MHz, DMSO-

d6): δ 168.8, 155.1, 131.7, 120.8, 113.6, 58.1, 55.0, 52.0. ESI-TOF. m/z calcd for
C44H57N8O8 (M+H)+, 825.4299, found 825.4284.

5.2c.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(p-

tolyl)acetamide). The title compound was obtained as a white powder (0.375 g) yield
(q). 1H NMR (400 MHz, DMSO-d6): δ 10.05 (4H, broad s); 7.47 (8H, d, J = 6.6 Hz); 7.03
(8H, d, J = 6.6 Hz); 3.26 (16H, s); 2.82 (8H, broad s); 2.22 (12H, s).

13

C NMR (100

MHz, DMSO-d6): δ 169.0, 135.9, 131.9, 128.7, 119.3, 58.1, 52.3, 20.1 ESI-TOF. m/z
calcd for C44H57N8O4 (M+H)+, 761.4503, found 761.4529.

5.2d.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-

nitrophenyl)acetamide). The title compound was obtained as a yellow powder (0.437 g)
yield (q). 1H NMR (400 MHz, DMSO-d6): δ 10.69 (4H, broad s); 8.10 (8H, s); 7.81 (8H,
s); 3.39 (16H, s); 2.87 (8H, broad s).

13

C NMR (100 MHz, DMSO-d6): δ 170.2, 144.5,

142.0 124.3, 118.7, 57.7, 52.0. ESI-TOF. m/z calcd for C40H45N12O12 (M+H)+, 885.3280,
found, 885.3254.

5.2e.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-

chlorophenyl)acetamide). The title compound was obtained as a white powder (0.394
g) yield 94%. 1H NMR (400 MHz, DMSO-d6): δ 10.6 (4H, broad s); 7.64 (8H, d, J = 8.8
Hz); 7.26 (8H, d, J = 8.8 Hz); 3.37 (16H, s); 2.78 (8H, broad s).

13

C NMR (100 MHz,

DMSO-d6): δ 169.5, 137.4, 128.1, 126.6, 120.8, 57.8, 51.7. ESI-TOF. m/z calcd for
C40H45Cl4N8O4 (M+H)+, 841.2318, found, 841.2325.
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General Procedure for Complexation of Tetra Substituted Cyclen Products 5.3a-e,
5.4a-e
To a stirring solution of appropriate tetra substituted cyclen (5.2a-e) (0.07 mmol) in 4 ml
1:1 H2O: dioxane, DyCl3 or TmCl3 (0.07 mmol) was added and the reaction was stirred
over a period of 1- 4 days at 60 °C - 80 °C. The complexation was monitored by UPLC
MS and upon completion, the reaction mixture was concentrated and redissolved in 1 ml
H2O followed by dialysis (for 3 days) against water to remove any unchelated
lanthanides.

5.3a.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-

phenylacetamide), thulium(III) chloride. The title compound was obtained as a white
powder (41 mg, 67%). ESI-TOF. m/z calcd for C40H46N8O4Tm (M-2H)+, 871.2984,
found 871.2974.

5.3b.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-

methoxyphenyl)acetamide), thulium(III) chloride. The title compound was obtained as
a white powder (58 mg, 83%). ESI-TOF. m/z calcd for C44H54N8O8Tm (M-2H)+,
991.3407, found 991.3387.

5.3c.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(p-

tolyl)acetamide), thulium(III) chloride. The title compound was obtained as a white
powder (30 mg, 46%). ESI-TOF. m/z calcd for C44H54N8O4Tm (M-2H)+, 927.3610,
found 927.3647.
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5.3d.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-

nitrophenyl)acetamide), thulium(III) chloride. The title compound was obtained as a
yellow powder (61mg, 82%). ESI-TOF. m/z calcd for C40H42N12O12Tm (M-2H)+,
1051.2387, found 1051.2408.

5.3e.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-

chlorophenyl)acetamide), thulium(III) chloride. The title compound was obtained as a
white powder (40 mg, 56%). ESI-TOF. m/z calcd for C40H42Cl4N8O4Tm (M-2H)+,
1007.1425, found 1007.1412.

5.4a.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-

phenylacetamide), dysprosium(III) chloride. The title compound was obtained as a
white powder (45 mg, 75%). ESI-TOF. m/z calcd for C40H46N8O4Dy (M-2H)+, 866.934,
found 866.2903.

5.4b.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-

methoxyphenyl)acetamide), dysprosium(III) chloride. The title compound was
obtained as a white powder (53 mg, 77%). ESI-TOF. m/z calcd for C44H54N8O8Dy (M2H)+, 986.3356, found, 986.3383.

5.4c.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(p-

tolyl)acetamide), dysprosium(III) chloride. The title compound was obtained as a
white powder (43 mg, 69%) ESI-TOF. m/z calcd for C44H54N8O4Dy (M-2H)+, 922.3560,
found 922.3586.
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5.4d.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-

nitrophenyl)acetamide), dysprosium(III) chloride. The title compound was obtained as
a yellow powder (45 mg, 62%). ESI-TOF. m/z calcd for C40H42N12O12Dy (M-2H)+,
1046.2337, found 1046.2336.

5.4e.

2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-(4-

chlorophenyl)acetamide), dysprosium(III) chloride. The title compound was obtained
as a white powder (49 mg, 70%). ESI-TOF. m/z calcd for C40H42Cl4N8O4Dy (M-2H)+,
1002.1375, found, 1002.1343.

5.3 Conclusion

A series of Dy3+ and Tm3+ para-substituted anilide CAs were synthesised and tested for
their ability to respond to pH changes in a range of interest for in vivo reporting. Poor
solubility of many of the compounds limited the possible measurements and prevented us
from making a complete comparison of structure and effects. Even with the limited
solubility, there were a number of interesting observations in the agents that were soluble.
It was observed that the unsubsituted anilines had a maximum CEST effect at a pH near
8, while the maximum CEST effect for the para-OMe agents was between pH 7-7.5. A
crystal structure indicated that a geometry of Tm3+ para-OMe is TSAP', which potentially
leads to the highly shifted signal at -83 ppm. While we have observed a signal for a Tm3+
agent above 100 ppm previously, we were unable to grow a crystal to help determine if
there was an inner sphere water.

A pH and concentration study was attempted to
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determine if Tm3+ para-OMe could be used as a ratiometric agent to measure pH in vivo,
independent of concentration, but due to solubility limitations, no suitable measurements
could be performed. Modifications of this ligand are currently underway to increase
solubility. With the lack of inner sphere water the Tm3+ aniline agents produce
appreciable amide CEST contrast without decreasing image signal intensity due to
lowering of the bulk water T2 relaxation time constant.
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5.4 Supplemental information

4.26

Figure S5.1.3+ CEST images of agents a) Tm3+ DOTAM Gly-Lys b) Tm3+ para-OMe (-43
ppm) c) Tm para-OMe (-83 ppm). Conditions: 20 mM, 5 s saturation, 15 µT, pH 7.0,
37 °C.
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Figure S5.2. 1H-NMR spectrum of 5.1a.

2.00
5

4

3

2

1

128

1a.esp
0.9

0.8

119.35

0.6

128.81

0.5

0.4

138.46

164.59

0.2

123.81

0.3

43.57

Normalized Intensity

0.7

0.1

0
170

160

150

140

130

120

110
100
90
80
Chemical Shift (ppm)

70

60

50

40

30

20

10

3.72

Figure S5.3. 13C-NMR spectrum of 5.1a.
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Figure S5.4. 1H-NMR spectrum of 5.1b.
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Figure S5.5. 13C-NMR spectrum of 5.1b.
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Figure S5.6. 1H-NMR spectrum of 5.1c.

2.00
5

3.00
4

3

2

1

1c.esp

119.37

129.18

130

0.9
0.8

20.43

43.57

0.6
0.5

135.96
132.81

0.4

164.35

Normalized Intensity

0.7

0.3
0.2
0.1
0
170

160

150

140

130

120

110
100
90
80
Chemical Shift (ppm)

70

60

50

40

30

20

10

4.35

Figure S5.7. 13C-NMR spectrum of 5.1c.
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Figure S5.8. 1H-NMR spectrum of 5.1d.
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Figure S5.9. 13C-NMR spectrum of 5.1d.
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Figure S5.10. 1H-NMR spectrum of 5.1e.
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Figure S5.11. 13C-NMR spectrum of 5.1e.
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Figure S5.12. 1H-NMR spectrum of 5.2a.

15.55 9.84
5

4

3

2

1

133

2a.esp
0.9

0.8

0.6

0.5

119.30

128.27

Normalized Intensity

0.7

0.4

58.05

51.94

138.45

169.32

0.2

122.99

0.3

0.1

0
170

160

150

140

130

120

110
100
90
80
Chemical Shift (ppm)

70

60

50

40

30

20

10

3.68

Figure S5.13. 13C-NMR spectrum of 5.2a.
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Figure S5.14. 1H-NMR spectrum of 5.2b.
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Figure S5.15. 13C-NMR spectrum of 5.2b.
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Figure S5.16. 1H-NMR spectrum of 5.2c.
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Figure S5.17. 13C-NMR spectrum of 5.2c.
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Figure S5.18. 1H-NMR spectrum of 5.2d.
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Figure S5.19. 13C-NMR spectrum of 5.2d.
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Figure S5.20. 1H-NMR spectrum of 5.2e.
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Figure S5.21. 13C-NMR spectrum of 5.2e.
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Chapter 6: Gold Nanoparticles Functionalized with
Gadolinium as T1 Based Contrast Agents

“Water-soluble gold nanoparticles (AuNP) functionalized with gadolinium (III)
via Michael addition for use as a MRI contrast” Submitted to Journal of Materials
Chemistry B, 2013. Manuscript #TB-ART-05-2013-020699.

6.1 Introduction

Gadolinium (Gd3+) based contrast agents (CA) for use in magnetic resonance imaging
(MRI) have been employed because of their ability to enhance the T1 relaxation of agent
bound water protons in vivo.1-7 This enhancement may highlight tissue involved in
pathological processes that allow leakage of the agent from the vasculature into the
tissue. The enhancement gained by Gd3+ based CAs is concentration dependent, such that
a hyperintense region is observed as local CA concentrations increase. Ultimately, the
enhancement of tissue contrast gained depends on the biodistribution of an agent, as a set
molar amount is delivered per patient to limit the possible side effects associate with
lanthanide-based CAs. To ensure that a site specific, effective concentration is achieved,
there have been efforts to develop nano-sized carriers to aid in the delivery of clinically
approved small molecule-based CAs. Covalent linkage of a small Gd3+ CA to a nanocarrier may increase its local concentration such that a single nanoparticle may provide
sufficient signal enhancement without relying the need of accumulation of a high
concentration of individual CAs. Strategies in this field include the development of
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dendrimers,8-12 liposomes,3, 13-15 micelles,16-18 polymers19-22 as well as silicon and goldbased nanoparticles.22-27 While each of these systems have their benefits and drawbacks
it is their size that will have the highest impact on their overall difference in MRI
properties compared to the single Gd3+ CA. It has been shown that the size of the nano
carrier is the limiting factor for a number of parameters such as loading of the chelator, in
vivo distribution, as well as the enhancement of relaxation gained by slower tumbling
molecules.2,

28

The size distribution of known carriers usually range from a few

nanometers (nm), to a few micrometers (µm). While loading of these nano carriers with
1000’s of chelators generates agents with excellent sensitivity their synthesis relies on
conventional nanoparticle synthesis methods.24 The drawback of using conventional
(one-pot) nanoparticle synthesis is the difficulty in reproducibility, lack of stability of the
CA on the nanoparticle and the need to control a large number of reaction conditions
where a change in one, may result in an undesired product that would not be suitable for
the development of clinically acceptable CAs where the control and characterization of
the structure is strict. A better approach is to utilize a previously prepared AuNP, where
the size and solubility can be controlled and that contains a reactive functionality capable
of undergoing a controlled interfacial reaction to introduce the CA covalently onto the
nanoparticle. To this end we describe the synthesis of Gd3+ modified water-soluble gold
nanoparticles (GdAuNP) that will have a reproducible and measureable number of
chelators (Scheme 6.1). To efficiently attach the Gd3+ chelator and enhance the prospect
for in vivo studies, we utilize a small water-soluble gold nanoparticle with a core size of 3
nm ± 1 nm that is functionalized with approximately 80 maleimide moieties at the
interface. Maleimide-modified AuNPs were chosen as they undergo efficient interfacial
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Michael addition when mixed with an appropriate nucleophile;

29, 30

in the present case

we utilize a Gd3+ CA, Gd3+DO3A-amine chelator (Scheme 6.1). 20,31

Scheme 6.1. Synthetic strategy used in the preparation of Maleimide-AuNP and the
subsequent interfacial Michael addition between Gd3+-DO3A-amine and Maleimide
AuNP.

All chemicals and solvents were used as received unless specified. All solvents were
HPLC grade, except water (18.2 MΩ cm-1). Organic extracts were dried with Na2SO4,
and solvents were removed under reduced pressure by rotary evaporation. Flash column
chromatography (FCC) was carried out using silica gel, mesh size 230-400 Å. Cellulose
ester dialysis membranes with MWCO of 6-8 KDa were used. In vivo contrast-enhanced
T1-weighted MR images were acquired using a 400 MHz horizontal bore small animal
MRI scanner equipped with a 30 mm millipede radio frequency coil (Agilent, Palo Alto,
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CA). Images were acquired before and immediately following intravenous (IV) injection
in the tail vein. NMR measurements were made on a spectrometer operating at 400 MHz.
Relaxation measurements were made for 4 different concentrations of CA using an
inversion recovery pulse sequence with 16 inversion times with a 2 second delay to
ensure full relaxation.

Preparation of Maleimide AuNP
Maleimide–AuNP was synthesized accordingly to our recently established procedure.29-31
Briefly, triethylene glycol monomethyl ether AuNP (Me-EG3-AuNP) was synthesized
mixing 3 equivalents of triethylene glycol monomethyl ether thiol with 1 equivalent of
AuHCl4 3H2O in a dry methanol/acetic acid solution (10:1), followed by slow addition of
10 equivalents of NaBH4 in water. The purified Me-EG3-AuNP underwent a placeexchange reaction with furan-protected-maleimide tetraethylene glycol–thiols ligands
(FP(maleimide)-EG4-SH). The resulting (FP(maleimide)–AuNPs were deprotected by
dissolving them in a toluene–acetonitrile (10:1) mixture and heating the system at 110 ºC
overnight under vigorous stirring. This method leads to small water-soluble maleimide–
AuNP with a gold core diameter of 3 ± 1 nm. The maleimide-AuNP contains ca. 0.50
µmol∙mg-1 of maleimide moieties as determined by thermogravimetric analysis and 1H
NMR spectroscopy. These AuNP were dissolved in acetonitrile to obtain a concentration
of 10 mg∙ml-1 and stored at -20 °C. Maleimide-AuNPs stored in this way were found to
be stable for months.
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Synthesis of DO3A-Amine
DO3A-amine was synthesized as previously reported.32 In short, cyclen was alkylated
with 3 eq. of ethyl bromoacetate in acetonitrile with potassium carbonate.

After

purification, the fourth alkylation was done with the previously reported boc-protected
amino ethyl chloroacetamide.

Complete deprotection was done with standard

deprotection conditions. TFA/DCM 1:1 for 30 min to remove the Boc group, followed by
drying and hydrolysis under basic conditions using 3.3 eq. of NaOH at 60 °C overnight.

Synthesis of Gd-DO3A-Amine
The agent was prepared using to previously reported conditions.20, 33 After deprotection
DO3A-amine was metallated with 1 eq of GdCl3 at pH 6. This reaction was monitored
by ESI-MS until metallation was complete. Finally, the complex was dialyzed at a 500
Dalton cutoff to remove free Gd3+.

Conjugation of CA onto Maleimide AuNP via Michael Addition
The nucleophile (Gd-DO3A-amine or DO3A-amine, 6 eq.) was stirred overnight with
AuNP-maleimide in a phosphate buffer at pH 7.5. The following day the pH of the
solution was lowered to 3-4 and the reaction mixture was dialyzed at a cutoff of 6-8 KDa
against water. The solution was then reduced in volume to achieve a concentration of 10
mM for in vivo testing. Gd-DO3A-amine-AuNPs were stored at -20 °C and were found
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to be stable for weeks. If stored in solution and at room temperature aggregation occurs
after a week.

FT-IR Measurements
Infrared spectra were collected using a Bruker Vector33 spectrometer. The blanks were
collected first by purging the instrument with nitrogen gas for 5 minutes and averaging
128 scans from 600 cm-1 to 4000 cm-1. Subsequently, the sample (~0.5 mg of AuNP)
was dispersed in dry KBr and packed into a pellet using a press. The AuNP spectra were
recorded in the same conditions of the blank, which was automatically subtracted.

Zeta potential measurements of DO3A-AuNP and Gd-AuNP
Zeta potential measurements were performed using a Zetasizer Nano-ZS (Malvern
Instrument). A solution of AuNP in PBS pH 7.5 was prepared with a concentration of 0.5
mg ml-1. 1 ml of this solution was inserted in a latex folded capillary cell equipped with
electrodes and the zeta potential was calculated by employing the Huckel approximation.

Relaxation measurements
The r1 for both the Gd3+-DO3A-amine and the GdAuNP were measured at 4
concentrations (Gd3+-DO3A-amine = 1 mM, 2 mM, 4 mM, 8 mM and GdAuNP = 1 mM,
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2 mM, 4 mM, 8.26 mM [Gd3+]) at pH 6.8 using an inverse recovery sequence with a 2
second delay to ensure full T1 relaxation between measurements. The slope of the plotted
T1 vs. concentration is measured and reported as the r1. r1 of Gd3+-DO3A-amine = 2.3
mM-1 s-1. r1 GdAuNP = 2.2 mM-1 S-1.

Gold and gadolinium concentration determination by ICP-OES.
ICP-OES measurements were done on a series of concentrations to allow for an accurate
measurement of both the concentration as well as the ratio of Au to Gd using 4
wavelengths for each element. It was found that the ratio of Au to Gd was 14:1. Using
the value of Au to maleimides calculated it is shown that 70% of the maleimides reacted
with the Gd-DO3A-amine to afford ca. 56 Gd3+ chelators present per NP.

MRI studies
Animals
To demonstrate MRI T1 contrast in vivo, a C57BL/6 mouse (8 months of age, weighing
~20 g) was anesthetized (induced using 4% isoflurane in oxygen and maintained using
1.5%–2.5% isoflurane in oxygen). To reduce motion, the abdomen of the mouse was
lightly taped to a MRI-compatible stage. The mouse was placed in a 30 mm Agilent
millipede coil.

Temperature was monitored with a rectal temperature probe, and

respiration was monitored with a respiratory sensor pad, which was connected to a
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pressure transducer placed over the thoracic/abdominal region (SA Instruments Inc.,
Stony Brook, NY). The mouse’s body temperature was maintained at 37 oC using a
warm-air feedback system. A catheter was placed in the tail vein using a 27-guage
needle. Three pre-injection T1-weighted MR images were acquired. Then 200 µL of 10
mM GdAuNP dissolved in water was injected directly into the tail vein at a constant rate
of 40 uL/min, with the mouse secured to the MRI compatible stage. Post-injection MR
image acquisition began within 2 min of injection. The animal procedure was performed
according to a protocol approved by the Western University Animal Use Subcommittee.
Same-slice pre- and post-injection images were acquired using a T1-weighted fast spin
echo (FSE) pulse sequence (TR/echo time = 500/10 ms, echo-train length = 4, 128 x 128
linear readout, 30.0 mm2 field of view, 5 slices, 2 mm slice thickness, 2 prescans, 4
averages) were acquired continuously for ~90 min through both kidneys.

6.2 Results and Discussion
Synthesis and Characterization of Maleimide-AuNP
Our synthetic approach for preparing small water-soluble Maleimide-AuNP is
summarized in scheme 6.1. This approach is based on a retro-Diels-Alder strategy where
the maleimide is first protected, followed by its deprotection only once the ligand is
attached to the gold core. The need for this protection is due the reactivity that thiols
have for Michael addition onto unprotected maleimides. The AuNP template (Me-EG3AuNP) that is employed as starting material is based on using the ω-mercapto triethylene
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glycol monomethyl ether as the base ligand.29 This ligand confers both water-solubility
and organic-solvent solubility to the nanoparticle. This amphiphilic property permits the
use of reactions in organic solvents, which is important in this case for the deprotection,
yet confers water-solubility to the final maleimide-AuNP. The latter is the target because
it can undergo the interfacial Michael addition reaction with the CA. In addition, the
ethylene glycol based ligands are expected to hinder protein adsorption in vivo which
should ensure prolongation of the AuNP circulation half-life and reduction of its
immunogenicity.34, 35 The triethylene glycol monomethyl ether gold nanoparticle (MeEG3-AuNP) was then subjected to a place-exchange reaction in presence of the furanprotected maleimide-tetraethylene glycol-thiol (FP(malemide)-EG4-SH). This reaction
was carried out by mixing 100 mg of Me-EG3-AuNP with 37.1 mg of FP(malemide)EG4-SH for 15 minutes in a 10:1 mixture of methanol and acetone. The (FP(malemide)EG4-AuNP was then purified by repeatedly washing a film of the nanoparticles with
hexanes, which removes the soluble, free thiols and leaves behind the insoluble AuNP.
The AuNP were then further purified by dialysis to completely remove any trace of free
thiol before the deprotection of the maleimide. The deprotection of the maleimide was
accomplished using a retro-Diels-Alder strategy; this involved dissolving the particles in
a mixture toluene/acetonitrile (10:1) and heating at 110 ºC overnight. Once the reaction
was completed the solvent and liberated furan were removed under vacuum and the film
of maleimide-AuNP was repeatedly washed with hexanes.

Characterization of the functionalized AuNPs was then done by 1H NMR spectroscopy in
D2O.29 In particular, the appearance of the following the signals after the place-exchange
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reaction where diagnostic: 6.60 ppm (alkene protons of the furan moiety), 5.25 ppm
(protons adjacent to the bridged oxygen), and at 3.07 ppm (protons adjacent to maleimide
carbonyl). After the retro-Diels-Alder reaction the olefinic signals at 6.60 and 5.25 ppm
and the protons adjacent to maleimide carbonyl at 3.07 in the FP(malemide)-EG4-AuNP
disappear concomitant with the appearance of the expected maleimide olefinic protons at
6.86 ppm, see supplemental information. The 1H NMR spectrum showed no indication of
the double hydrolysis products that would have appeared as a signal at 6.23 ppm, 29 or the
mono hydrolysis product that would have shown two broad doublets at 6.24 and 5.84
ppm. The target maleimide-AuNP was also characterized by thermogravimetric analysis
(TGA) and transmission electron microscopy (TEM). TEM showed a gold core size of 3
± 1 nm, while TGA showed the presence of 0.5 µmol of maleimide ligands per milligram
of AuNP.

From the combination of the 1H NMR, TGA and TEM data, and assuming that the AuNP
are spherical and that their size is monodisperse (3 nm) it is possible to calculate an
approximate molecular formula for the maleimide-AuNP. The number of gold atoms
(NAu) can be calculated using the following formula:

N

   d3  NA
6  M Au
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Where  is the density of the face centered cubic (fcc) gold lattice (19.3 g cm -3), d is the
average diameter of the nanoparticles in centimeters found from the TEM images, MAu is
the mole atomic weight of gold (196.9665 g mol-1), and NA is Avogadro constant.
The number of thiol ligands surrounding the gold core (NL) can be calculated using the
following formula:

NL 

N  M Au W%
(1  W% )  [MWMaleimideS  M %  MWMe EG 3S  (1  M % )]

Where W% is the percentage of mass loss due to the organic ligands found through TGA
measurements, MWMe-EG3-S is the molecular weight of the base thiolate ligand,
MWMaleimide-S is the molecular weight of the maleimide thiolates ligand, and M% is the
mole percentage of maleimide ligand.
Using these equations and determining the molar percentage of ligands from the 1H NMR
spectra, we can calculate an approximate nanoparticle formula of Au800(Me-EG3S)370(maleimide-EG4-S)80.

Interfacial Michael addition onto Maleimide-AuNP

To optimize the synthetic conditions for preparing the Gd3+-DO3A-amine-AuNP, a
model reaction was performed using the un-metalated DO3A-amine to avoid NMR line
broadening caused by Gd3+, which would hinder characterization. Using the uncomplexed
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ligand, DO3A-amine we could easily follow the course of the reaction using 1H NMR
spectroscopy observing the disappearance of the maleimide olefin protons signal at 6.86
ppm. The interfacial Michael addition reaction was performed by mixing DO3A-amine
(181 mg) with maleimide-AuNP (60 mg) in a buffered solution at pH 7.5. This mixture
was left overnight at room temperature. The amounts utilized correspond to ca. 6
equivalents of DO3-amine to every one maleimide; the total number of maleimide
moieties (80/AuNP) was estimated as outlined above. Although an alkaline pH is
required in order to avoid protonation of the amine nucleophile, it cannot be higher than
7.5 due to the propensity of the maleimide to hydrolyze in water (time scale of hours).29
Additionally, the solubility of Gd3+-DO3A-amine decreases at basic pHs. The model
reaction was monitored by 1H NMR spectroscopy following the disappearance of the
alkene protons signal at 6.86 ppm. Once it was evident that the maleimide had reacted,
the pH of the solution was lowered to 3-4 to re-dissolve the functionalized AuNP and the
unreacted nucleophile. This acidic solution was then dialyzed against water using a
membrane with a MWCO of 6-8 KDa to remove the excess nucleophile. The same
reaction conditions and purification method were then employed to synthesize Gd3+DO3A-amine modified AuNP. Importantly, the final Gd3+-DO3A-Amine-AuNP was
found to be well soluble in water at up to pH 7.4, while the Gd3+-DO3A-amine was found
to have a limited solubility at this pH.

The success of the interfacial Michael addition reaction and the covalent linking of the
CA were demonstrated by 1H NMR spectroscopy, FT-IR spectroscopy and Zeta potential
measurements. The 1H NMR spectrum of the purified Gd3+-DO3A-amine-AuNP showed
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the typical line broadening due to the presence of Gd3+. Figure 6.1 shows the FT-IR
spectra of maleimide-AuNP, DO3A-amine-AuNP and Gd3+-DO3A-amine-AuNP, and
confirms the success of our synthetic approach. The maleimide-AuNP spectrum (figure
6.1 a) shows the typical band at 2869 cm-1 due to the C-H stretching mode mainly due to
the ethylene glycol units of the ligands, and maleimide’s C=

stretching band at 1735

cm-1 (asymmetric) and at 1704 cm-1 (symmetric). The presence of the DO3A chelator is
supported by the appearance of a broad band at 3600-3000cm-1 that is due to the N-H
stretching. In addition the increase in the intensity ratio of the C=O stretches due to the
maleimide moiety at 1704 cm-1 to 1735 cm-1 indicates the change in the C=O of the
maleimide due to the Michael addition. This along with the appearance of the stretch at
1612cm-1 due to the amide II band of the DO3A-amine (especially visible for the Gd3+DO3A-amine-AuNP, figure 6.1 c) further supports the formation of Gd3+-DO3A-amineAuNP.

Zeta potential measurements were carried out at pH 7.5 on the maleimide-AuNP, on
DO3A-amine-AuNP and on Gd3+-DO3A-amine-AuNP, and were used to investigate the
stability of the nanoparticle in aqueous solution and to measure the change in the surface
charge after each interfacial reaction outlined in Scheme 6.1. The Zeta potential was
found to shift from -36 ± 3 mV to -53± 3 mV from the maleimide-AuNP to the DO3Aamine-AuNP because of the presence of three deprotonated carboxylic groups per every
interfacial Michael addition adduct. The presence of the cationic metal centre in Gd3+DO3A-amine-AuNP causes then the zeta potential to shift back to -30 ± 3 mV because
Gd3+ compensates the negative charges carried by the carboxylates. A potential of -30 ±
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3 mV for the final product confirms the visual observation that the Gd3+-DO3A-amineAuNP form a stable solution even at a slightly basic pH.

Finally, the metal composition (Au and Gd) of the nanoparticle was investigated by ICPOES. From these results, we determined the ratio of Au:Gd and this was used to
calculate the number of Gd chelators that had successfully reacted with maleimide
moieties.

ICP analysis showed that a ratio of 14:1 Au:Gd atoms was present after the

interfacial Michael addition which indicated that 56 of the possible 80 maleimide sites
underwent Michael addition (70% yield of the interfacial reaction). The remaining 30%
of the maleimides likely underwent the mono-hydrolysis as observed through 1H NMR
spectroscopy for the model reaction using DO3A-amine (Supplemental Figure 4).

The

incomplete reaction may also be related to the large size of the chelator compared and
possible charge repulsion between the chelators limiting a higher loading. It should be
noted that when an excessively large number of chelators are present there is the
possibility that the exchange of bound water will not be efficient, resulting in a
detrimental effects on the relaxation and performance as a CA.
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Figure 6.1. IR spectra of a) Gd3+AuNP b) DO3A-AuNP c) maleimide-AuNP.

Relaxation measurements
Relaxation measurements were made on the individual Gd3+ chelator as well as the
Gd3+AuNP at four concentrations (Gd3+DO3A-amine = 1 mM, 2 mM, 4 mM, 8 mM.
Gd3+AuNP = 1 mM, 2 mM, 4 mM, 8.26 mM) at pH 6.8 at 37 °C. The relaxation of Gd3+DO3A-amine as well as Gd3+AuNP was the same within error. (r1 Gd3+-DO3A-amine =
2.3 mM-1 s-1, r1 Gd3+AuNP = 2.2 mM-1 s-1) (Figure 6.2).
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Figure 6.2. a) Images of phantoms of Gd-AuNP at concentrations 1 mM, 2 mM, 4mM
and 8.26 mM at pH 6.8 and 37 °C. b) Calibration curve of (a). The slope of the graph is
the r1 GdAuNP = 2.2 mM-1S-1.

These values are comparable to other small molecule CAs at 9.4 T.36 While it has been
shown that a large, slower tumbling CA will have a more efficient relaxation compared to

156

small fast tumbling molecules this is not observed for our Gd3+AuNP. The free rotation
of the chelator with respect to the AuNP is thought to limit the enhancement of slow
tumbling and therefore the relaxation of the AuNP is the same as the free chelator. 5, 28
While these results indicate that there is no enhancement to the single Gd3+ chelator it is
equally important to note that no decrease in relaxivity per chelator is noticed. This is
important in the formation of AuNPs due to the likelihood that Gd3+ chelators are located
in close proximity to each other, which has the potential to limit the access to the
exchangeable proton source of the free pool resulting in a decrease in efficiency of
relaxation. Because there is no decrease in relaxivity per Gd3+ the overall r1 of the NP is
56 times the single r1 of the Gd3+ CA and is therefore 123 mM-1 s-1 which is sufficient to
ensure a local concentration high enough for in vivo imaging.

In vivo evaluation
With the Gd3+AuNP in hand, as a proof of concept we investigated its ability to act as a
contrast agent in mice. Figure 6.3 shows the in vivo MR T1 images of the kidneys of a
mouse pre injection (a), 5 min post injection of a 0.1 mmol/kg [Gd] dose (b) and
subtracted image (c). All in vivo images are from identical oblique slices and both
kidneys are contained in the slice. Regions of interest containing the renal vasculature
(solid line) and the medulla (dashed line) were identified using the 5 min post injection
MR image as shown in Figure 6.3. Signal intensities collected from the regions of
interest throughout the entire experiment are displayed in Figure 6.4.
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An increase in signal intensity of roughly 200% was observed in the vascular region of
both kidneys along with an enhancement of ~100% within in the medulla for each
kidney. The signal enhancement was observed throughout the entire monitoring period
of 90 min as shown in the wash in and out profiles, Figure 6.4. This elongated period of
filtration is significant as it indicates that the agent is circulating in the blood for an
extended period of time, which in turn should allow a generous period for imaging. The
small size and prolonged circulation of Gd3+AuNP contrast agent may allow for sufficient
agent accumulation in pathological tissue, such as cancerous tumours where the
vasculature membranes are permeable to circulating agents.37 It should be noted that
because of the small size of these nanoparticles, filtration would be primarily through
renal excretion and as such is consistent with the observed enhancement in the kidneys
and for this reason we began our in vivo testing of the renal system. Although the
contrast enhancement is an important property, equally so is the toxicity of the contrast
agent. The Gd3+AuNP contrast agent displayed negligible toxicity during imaging and
the mouse showed no ill effects 24 h post scan.
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Figure 6.3. T1 weighted images of kidneys of 0.1 mmol/kg of Gd3+AuNP based on Gd
concentration via tail injection. Left) Pre-injection Middle) 5 min post injection Right)
Subtracted image of pre and post.

Figure 6.4. (Left) Signal enhancement of the vascular region of kidney 1 (Top) and
kidney 2 (Bottom) showing a 200% signal enhancement immediately after injection with
the enhancement falling to 50-100% at 90min. (Right) Signal enhancement of the
medulla region of the kidney 1 (Top) and kidney 2 (Bottom) showing an enhancement of
~50% consistently throughout the 90 min of imaging.
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6.3 Conclusion

We have demonstrated the ability to functionalize Au nanoparticles to nearly 70% under
aqueous conditions to afford contrast agents that are suitable for MRI with over 50 Gd3+
chelators per AuNP. The GdAuNP are soluble at physiological pH and permit a higher
concentration of CA to be delivered compared to the unbound CA that has a limited
solubility at the same pH. We have developed a method to produce AuNP’s of discrete
size that function as their original clinically approved CA that are non toxic in vivo.
Moving forward we are beginning to prepare agents that will benefit from the slow
tumbling of the nano-sized agents as well as expanding on our imaging modalities. By
employing AuNPs as our scaffold for our Gd3+ MRI CA we also have a strong X-Ray
absorber that is suitable as a multimodal agent for MRI/computed tomography.22-25
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6.4 Supplemental information

S6.1. 1H NMR spectrum of Me-EG*3-AuNP referenced to residual H2O (*).

S6.2. 1H NMR spectrum of FPMaleimide-AuNP
referenced to residual H2O (*).
*

*
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S6.3. 1H NMR spectrum of Maleimide-AuNP referenced to residual H2O (*).
Water
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S6.4. 1H NMR spectrum of DO3A-Amine-AuNP referenced to residual H2O (*). The
peaks at 5.84 ppm and 6.24 ppm are related to the hydrolysis of the maleimide to the
corresponding maleamic acid.
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S6.5. 1H NMR spectrum of Gd-DO3A-Amine-AuNP.
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S6.7. H NMR Spectrum of 2-N-Chloroacetyl-1-N-(Boc)ethylene Diamine
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S6.9. 1H NMR Spectrum of Tri(ethyl ester) Mono(Boc)Ethylene Diamine Cyclen

165

6.5 References
1.

S. Aime, C. Cabella, S. Colombatto, S. G. Crich, E. Gianolio and F. Maggioni, J.
Magn. Reson. Imaging, 2002, 16, 394-406.

2.

S. Aime, M. Botta and E. Terreno, Adv. Inorg. Chem., 2005, 57, 173-237.

3.

D. D. Castelli, E. Gianolio, S. G. Crich, E. Terreno and S. Aime, Coord. Chem.
Rev., 2008, 252, 2424-2443.

4.

A. D. Sherry, P. Caravan and R. E. Lenkinski, J. Magn. Reson. Imaging, 2009,
30, 1240-1248.

5.

P. Caravan, Chem. Soc. Rev., 2006, 35, 512-523.

6.

P. Caravan, J. J. Ellison, T. J. McMurry and R. B. Lauffer, Chem. Rev., 1999, 99,
2293-2352.

7.

S. Laus, R. Ruloff, E. Toth and A. E. Merbach, Chem. Eur. J., 2003, 9, 35553566.

8.

J. A. Pikkemaat, R. T. Wegh, R. Lamerichs, R. A. van de Molengraaf, S.
Langereis, D. Burdinski, A. Y. F. Raymond, H. M. Janssen, B. F. M. de Waal, N.
P. Willard, E. W. Meijer and H. Grull, Contrast Media Mol. Imaging, 2007, 2,
229-239.

9.

M. Longmire, P. L. Choyke and H. Kobayashi, Curr. Top. Med. Chem., 2008, 8,
1180-1186.

10.

M. A. Mintzer and M. W. Grinstaff, Chem. Soc. Rev., 2011, 40, 173-190.

11.

E. Toth, D. Pubanz, S. Vauthey, L. Helm and A. E. Merbach, Chem. Eur. J.,
1996, 2, 1607-1615.

12.

G. M. Nicolle, E. Toth, H. Schmitt-Willich, B. Raduchel and A. E. Merbach,
Chem. Eur. J., 2002, 8, 1040-1048.

13.

V. Weissig, J. Babich and V. Torchilin, Colloid Surf. B-Biointerfaces, 2000, 18,
293-299.

14.

E. Terreno, A. Sanino, C. Carrera, C. D. Delli, G. B. Giovenzana, A. Lombardi,
R. Mazzon, L. Milone, M. Visigalli and S. Aime, J. Inorg. Biochem., 2008, 102,
1112-1119.

15.

E. Terreno, W. Dastru, D. D. Castelli, E. Gianolio, S. G. Crich, D. Longo and S.
Aime, Curr. Med. Chem., 2010, 17, 3684-3700.

166

16.

G. M. Nicolle, E. Toth, K. P. Eisenwiener, H. R. Macke and A. E. Merbach, J.
Biol. Inorg. Chem., 2002, 7, 757-769.

17.

J. P. Andre, E. Toth, H. Fischer, A. Seelig, H. R. Macke and A. E. Merbach,
Chem. Eur. J., 1999, 5, 2977-2983.

18.

M. Grogna, R. Cloots, A. Luxen, C. Jerome, C. Passirani, N. Lautram, J. F.
Desreux and C. Detrembleur, Polym. Chem., 2010, 1, 1485-1490.

19.

A. Soleimani, F. Martinez, V. Economopoulos, P. J. Foster, T. J. Scholl and E. R.
Gillies, J. Mater. Chem. B, 2013, 1, 1027-1034.

20.

M. Grogna, R. Cloots, A. Luxen, C. Jerome, J.-F. Desreux and C. Detrembleur, J.
Mater. Chem., 2011, 21, 12917-12926.

21.

K. M. Atkins, F. M. Martinez, A. Nazemi, T. J. Scholl and E. R. Gillies, Can. J.
Chem., 2011, 89, 47-56.

22.

M. Beija, Y. Li, H. T. Duong, S. Laurent, L. Vander Elst, R. N. Muller, A. B.
Lowe, T. P. Davis and C. Boyer, J. Mater. Chem., 2012, 22, 21382-21386.

23.

C. Alric, J. Taleb, G. L. Duc, C. Mandon, C. Billotey, A. L. Meur-Herland, T.
Brochard, F. Vocanson, M. Janier, P. Perriat, S. Roux and O. Tillement, J. Am.
Chem. Soc., 2008, 130, 5908-5915.

24.

J.-A. Park, H.-K. Kim, J.-H. Kim, S.-W. Jeong, J.-C. Jung, G.-H. Lee, J. Lee, Y.
Chang and T.-J. Kim, Bioorg. Med. Chem. Lett., 2010, 20, 2287-2291.

25.

Y. Song, X. Xu, K. W. MacRenaris, X.-Q. Zhang, C. A. Mirkin and T. J. Meade,
Angew. Chem. Int. Ed., 2009, 48, 9143-9147.

26.

J.-L. Bridot, A.-C. Faure, S. Laurent, C. Riviere, C. Billotey, B. Hiba, M. Janier,
V. Josserand, J.-L. Coll, L. Vander Elst, R. Muller, S. Roux, P. Perriat and O.
Tillement, J. Am. Chem. Soc., 2007, 129, 5076-5084.

27.

P.-J. Debouttiere, S. Roux, F. Vocanson, C. Billotey, O. Beuf, A. FavreReguillon, Y. Lin, S. Pellet-Rostaing, R. Lamartine, P. Perriat and O. Tillement,
Adv. Funct. Mater., 2006, 16, 2330-2339.

28.

P. Caravan, Acc. Chem. Res., 2009, 42, 851-862.

29.

P. Gobbo and M. S. Workentin, Langmuir, 2012, 28, 12357-12363.

30.

K. D. Hartlen, H. Ismaili, J. Zhu and M. S. Workentin, Langmuir, 2012, 28, 864871.

31.

P. Gobbo, M. C. Biesinger and M. S. Workentin, Chem. Commun., 2013, 49,
2831-2833.

167

32.

L. S. Natrajan, A. J. L. Villaraza, A. M. Kenwright and S. Faulkner, Chem.
Commun., 2009, 6020-6022.

33.

L. Tei, G. Gugliotta, Z. Baranyai and M. Botta, Dalton Trans., 2009, 0, 97129714.

34.

J. Lu, M. Shi and M. S. Shoichet, Bioconjugate Chem., 2008, 20, 87-94.

35.

A. Taylor, K. M. Wilson, P. Murray, D. G. Fernig and R. Levy, Chem. Soc. Rev.,
2012, 41, 2707-2717.

36.

M. Milne, K. Chicas, A. Li, R. Bartha and R. H. E. Hudson, Org. Biomol. Chem.,
2012, 10, 287-292.

37.

H. F. Dvorak, J. A. Nagy, J. T. Dvorak and A. M. Dvorak, Am. J. Pathol., 1988,
133, 95-109.

168

Chapter 7: Conclusion

The main theme of this thesis, was the synthesis of novel MRI contrast agents. While it
is possible to synthesize a large array of agents with properties that are suitable for MR
imaging, it is a more difficult task to rationally design agents with predictable properties.
My investigations over the past four years have contributed to a greater understanding of
the structure-properties relationships of cyclen-based ParaCEST contrast agents and will
impact future rational CA design.

The studies described in this thesis began by designing a central moiety that would enable
us to perform “click” reactions using targeting agents such as carbohydrates. While
investigating the potential of this agent, it was discovered that parent alkyne-derivatized
DOTAM had exceptional temperature sensitivity as described in chapter 2. Since the
appearance of the publication (chapter 2), we were contacted by the NIST with the goal
of using this agent as a temperature probe during NMR studies. These studies are still
ongoing.

Using the “click” scaffold molecule (chapter 2), sugar-modified contrast agents were
prepared and their potential as T1 and paraCEST agents was evaluated, as described in
chapter 3. Attempts to understand the structural-property relationship of these agents
proved to be rather difficult due to multiple, simultaneous contributing factors, such as;
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size, water exchange rates and hydrogen bonding ability of the pendant groups.
However, this study highlighted the potential of the exchangeable amide protons to be
used as paraCEST agents and this led us to develop a series of high shifting amide agents.

During the evaluation of a series of high shifting amide based paraCEST agents it was
observed that an agent with an exchangeable proton past 100 ppm could be developed
(chapter 4). Evaluating this agent showed that signals outside of 100 ppm will allow for
in vivo detection while minimizing interference from magnetization transfer effects. This
is a significant observation and research direction since the observation of bona fide
ParaCEST contrast in vivo is severely affected from endogenous MT to such an extent
that makes this imaging modality completely impractical.

Thus, overcoming this

limitation is critical in moving the field of ParaCEST MRI toward clinical application.

Next, we chose to tackle a second MR property that hinders in vivo imaging, namely T2
shortening of lanthanide based agents due to T2 exchange. By designing and synthesizing
agents that do not possess an inner sphere water, we were able to demonstrate how the
signal to noise increases substantially, which in turn increases the sensitivity of
paraCEST imaging. Clearly, the next step is to combine properties of a highly shifted
amide signal with agents that have long T2 values to develop agents that are suitable for
in vivo paraCEST imaging.

170

Finally, our final work focused on developing highly loaded T1 nanoparticles using an
interfacial Michael addition. Collaborating with a research group that had previously
developed a water soluble gold nanoparticle we were able to synthesis an agent
containing over 50 Gd3+ chelators to grant a high T1 relaxation value at 9.4 T suitable for
in vivo imaging which was demonstrated in chapter 6.

The culmination of the research described in this thesis provides the groundwork for
further development of ParaCEST contrast agents that have high shifted amides, with no
inner sphere water that are suitable for in vivo imaging.
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